epocrates logo
epocrates logo
epocrates logo
  • 0

Drugs


Formulary
No Formulary Selected

Classes

  • All Drugs
  • Allergy/Cold/ENT
  • Anesthesia/Pain Management
  • Asthma/Pulmonary
  • Cardiovascular
  • Dental/Oral Care
  • Dermatologic
  • Diagnostic
  • Emergency
  • Endocrine/Metabolism
  • Gastrointestinal
  • Hematology/Oncology
  • Immunizations
  • Immunology
  • Infectious Disease
  • Nephrology/Urology
  • Neurologic
  • Nutrition/Electrolytes
  • Obstetrics/Gynecology
  • Ophthalmic
  • Psychiatric
  • Rheumatologic

Drug Names

# A B C D E F G H  I  J K L M N O P Q R S T U V W X Y Z
A+D Anti-Chafing Ointment
A+D Diaper Rash Cream
A+D First Aid Ointment
A+D Incontinence Support Skin Protectant & Rash Ointment
A+D Medicated Rash Ointment
A+D Original Ointment
A+D Overnight Healing Rash Ointment
abacavir
abacavir/dolutegravir/lamivudine
abacavir/lamivudine
abacavir/lamivudine/zidovudine
abaloparatide
abametapir topical
abatacept
Abecma
Abelcet
abemaciclib
Abigale
Abigale Lo
Abilify
Abilify Asimtufii
Abilify Discmelt
Abilify Maintena
Abilify MyCite
abiraterone acetate
abiraterone acetate micronized
Ablysinol
abobotulinumtoxinA
Abraxane
Abreva
Abreva Rapid Pain Relief
Abrilada (adalimumab-afzb)
abrocitinib
Abrysvo
Absorica
Absorica LD
Abstral
acalabrutinib
ACAM2000
acamprosate
Acanya
acarbose
Accolate
Accrufer
AccuNeb
Accupril
Accuretic
Accutane
acebutolol
aceclidine ophthalmic
Aceon
Acetadote
acetaminophen
acetaminophen rectal
acetaminophen/aspirin
acetaminophen/aspirin/caffeine
acetaminophen/aspirin/diphenhydramine
acetaminophen/caffeine
acetaminophen/caffeine/dihydrocodeine
acetaminophen/caffeine/pyrilamine
acetaminophen/chlorpheniramine
acetaminophen/chlorpheniramine/dextromethorphan
acetaminophen/chlorpheniramine/dextromethorphan/phenylephrine
acetaminophen/chlorpheniramine/dextromethorphan/pseudoephedrine
acetaminophen/chlorpheniramine/phenylephrine
acetaminophen/codeine
acetaminophen/dextromethorphan
acetaminophen/dextromethorphan/guaifenesin
acetaminophen/dextromethorphan/phenylephrine
acetaminophen/dextromethorphan/phenylephrine/guaifenesin
acetaminophen/dextromethorphan/pseudoephedrine
acetaminophen/diphenhydramine
acetaminophen/diphenhydramine/phenylephrine
acetaminophen/doxylamine/dextromethorphan
acetaminophen/doxylamine/dextromethorphan/phenylephrine
acetaminophen/guaifenesin
acetaminophen/ibuprofen
acetaminophen/pamabrom
acetaminophen/pamabrom/pyrilamine
acetaminophen/phenylephrine
acetaminophen/phenylephrine/guaifenesin
acetaminophen/pseudoephedrine
acetaminophen/triprolidine/dextromethorphan
acetaminophen/triprolidine/dextromethorphan/phenylephrine
acetazolamide
acetic acid otic
acetohydroxamic acid
acetylcholine intraocular
acetylcysteine
Aciphex
Aciphex Sprinkle
acitretin
aclidinium bromide inhaled
aclidinium bromide/formoterol inhaled
Aclovate
acoltremon ophthalmic
acoramidis
acrivastine/pseudoephedrine
Actemra
Acthar Gel
ActHIB
Acticlate
Actidose with Sorbitol
Actidose-Aqua
Actigall
Actimmune
Actiq
Activase
Activella
Actonel
Actonel with Calcium
ACTOplus met
ACTOplus met XR
Actos
Acular
Acular LS
Acuvail
Acuvue Theravision with Ketotifen
acyclovir
acyclovir oropharyngeal
acyclovir topical
acyclovir/hydrocortisone topical
Aczone
Adacel
adagrasib
Adakveo (crizanlizumab-tmca)
Adalat CC
adalimumab
ADAMTS13, recombinant
adapalene topical
adapalene/benzoyl peroxide topical
Adasuve
Adbry (tralokinumab-ldrm)
Adcetris
Adcirca
Adderall
Adderall XR
Addyi
adefovir dipivoxil
Adempas
Adenocard
Adenoscan
adenosine
adenovirus type 4 and type 7 vaccine, live oral
Adhansia XR
Adipex-P
Adlarity
Adlyxin
Admelog
ado-trastuzumab emtansine
Adoxa
Adquey
Adrenaclick
Adrenalin
Adriamycin
Adrucil
Adstiladrin (nadofaragene firadenovec-vncg)
aducanumab
Aduhelm (aducanumab-avwa)
Advair Diskus
Advair HFA
Advate
Advil
Advil Allergy & Congestion Relief
Advil Allergy Sinus
Advil Cold & Sinus
Advil Dual Action with Acetaminophen
Advil Dual Action with Acetaminophen Back Pain
Advil Migraine
Advil Multi-Symptom Cold & Flu
Advil PM
Advil Sinus Congestion & Pain
Advil Targeted Relief Cream
Adynovate
Adzenys ER
Adzenys XR-ODT
Adzynma (ADAMTS13, recombinant-krhn)
Aemcolo
afamelanotide
afamitresgene autoleucel
afatinib
Afeditab CR
aficamten
Afinitor
Afinitor Disperz
aflibercept intravitreal
Afluria
Afrezza
Afrin Allergy Sinus
Afrin No Drip Allergy Sinus
Afrin No Drip Allergy Sinus Night
Afrin No Drip Extra Moisturizing
Afrin No Drip Night
Afrin No Drip Original
Afrin No Drip Severe Congestion
Afrin Original
Afrin Severe Congestion
Afstyla
agalsidase beta
Agamree
Aggrastat
Aggrenox
Agrylin
Ahzantive (aflibercept-mrbb)
Aimovig (erenumab-aooe)
air polymer-type A
AirDuo Digihaler
AirDuo RespiClick
Airsupra
Ajovy (fremanezumab-vfrm)
AK-Dilate
AK-Poly-Bac
Akeega
Aklief
Akne-mycin
Akovaz
Akten
Aktipak
Akynzeo
Akynzeo IV
Ala-hist IR
Alahist CF
Alahist D
Alahist DM
Alahist PE
Alamast
Alavert
Alavert D-12 Hour
Alaway
albendazole
Albenza
albiglutide
Albuked
albumin (human)
Albuminar
Albuminex (albumin (human)-kjda)
AlbuRx
Albutein
albuterol
albuterol inhaled
albuterol/budesonide inhaled
alcaftadine ophthalmic
Alcaine
alclometasone topical
Aldactazide
Aldactone
Aldara
aldesleukin
Aldomet
Aldurazyme
Alecensa
alectinib
alemtuzumab
alendronate
alendronate/cholecalciferol
Alesse
Aleve
Aleve Arthritis Pain Gel
Aleve Back & Muscle Pain
Aleve Headache Pain
Aleve PM
Aleve-D Sinus & Cold
AleveX Lotion
AleveX Spray
Alfenta
alfentanil
alfuzosin
alglucosidase alfa
Alhemo (concizumab-mtci)
Alimta
Alinia
Aliqopa
alirocumab
aliskiren
aliskiren/hydrochlorothiazide
alitretinoin topical
Alka-Seltzer Cool Action Heartburn Relief Gum
Alka-Seltzer Extra Strength Heartburn ReliefChews
Alka-Seltzer Extra Strength Upset Stomach Relief
Alka-Seltzer Hangover Relief
Alka-Seltzer Heartburn + Gas ReliefChews
Alka-Seltzer Original
Alka-Seltzer Plus Cold & Flu FizzyChews
Alka-Seltzer Plus Cough & Sore Throat FizzyChews
Alka-Seltzer Plus Maximum Strength Cold & Cough
Alka-Seltzer Plus Maximum Strength Cold & Cough PowerMax
Alka-Seltzer Plus Maximum Strength Cold & Flu Day
Alka-Seltzer Plus Maximum Strength Cold & Flu Day PowerMax
Alka-Seltzer Plus Maximum Strength Cold & Flu Night
Alka-Seltzer Plus Maximum Strength Cold & Flu Night PowerMax
Alka-Seltzer Plus Maximum Strength Cough & Chest Congestion Power...
Alka-Seltzer Plus Maximum Strength Cough, Mucus & Congestion Powe...
Alka-Seltzer Plus Maximum Strength Cough, Mucus & Congestion Powe...
Alka-Seltzer Plus Maximum Strength Sinus Congestion & Pain PowerF...
Alka-Seltzer Plus Maximum Strength Sinus Congestion & Pain PowerM...
Alka-Seltzer Plus Maximum Strength Sinus, Allergy & Cough PowerMa...
Alka-Seltzer Plus Severe Cold & Cough PowerFast Fizz
Alka-Seltzer Plus Severe Cold & Flu Day
Alka-Seltzer Plus Severe Cold & Flu Night
Alka-Seltzer Plus Severe Cold & Flu PowerFast Fizz
Alka-Seltzer Plus Severe Cold PowerFast Fizz
Alka-Seltzer Plus Severe Cold PowerFast Fizz Night
Alka-Seltzer Plus Severe Cold PowerFast Fizz Non-Drowsy
Alka-Seltzer Plus Severe Sinus, Cold & Cough
Alka-Seltzer Upset Stomach Relief
Alkeran
Alkindi Sprinkle
Allegra Allergy 12 Hour
Allegra Allergy 24 Hour
Allegra Hives 24 Hour
Allegra-D 12 Hour Allergy & Congestion
Allegra-D 24 Hour Allergy & Congestion
Aller-chlor
Alli
allogeneic cell therapy
allopurinol
Allzital
almotriptan
Alocril
alogliptin
alogliptin/metformin
alogliptin/pioglitazone
Alomide
Aloprim
Alora
alosetron
Aloxi
alpelisib
alpha-tocopherol (vitamin E)
alpha1-proteinase inhibitor
Alphagan P
Alphanate
alprazolam
Alprolix
alprostadil
alprostadil intracavernous
alprostadil intraurethral
Alrex
Alsuma
Altabax
Altace
Altafluor Benox
Altavera
alteplase
alteplase intracatheter
Altoprev
Altreno
Altuviiio (antihemophilic factor (recombinant), Fc-VWF-XTEN fusio...
aluminum acetate topical (modified Burow's solution)
aluminum chloride topical
aluminum hydroxide
aluminum hydroxide/magnesium carbonate
aluminum hydroxide/magnesium hydroxide
aluminum hydroxide/magnesium hydroxide/simethicone
Alunbrig
Alvaiz
Alvesco
alvimopan
Alyacen 1/35
Alyacen 7/7/7
Alyftrek
Alyglo (immune globulin human-stwk)
Alymsys (bevacizumab-maly)
Alyq
Amabelz
amantadine
Amaryl
Ambien
Ambien CR
AmBisome
ambrisentan
amcinonide topical
Ameluz
Amerge
Amethia
Amethia Lo
Amethyst
Amicar
Amidate
amifampridine
amifostine
amikacin
amikacin liposomal inhaled
Amikin
amiloride
amiloride/hydrochlorothiazide
aminocaproic acid
aminolevulinic acid topical
aminophylline
amiodarone
amisulpride
Amitiza
amitriptyline
amivantamab
amivantamab/hyaluronidase
Amjevita (adalimumab-atto)
amlodipine
amlodipine/atorvastatin
amlodipine/benazepril
amlodipine/celecoxib
amlodipine/olmesartan medoxomil
amlodipine/valsartan
amlodipine/valsartan/hydrochlorothiazide
ammonium lactate topical
Ammonul
Amnesteem
Amondys 45
amoxapine
amoxicillin
amoxicillin/clavulanate
Amoxil
Amphadase
amphetamine
Amphocin
Amphojel
Amphotec
amphotericin B cholesteryl sulfate
amphotericin B deoxycholate
amphotericin B lipid complex
amphotericin B liposomal
ampicillin
ampicillin/sulbactam
Ampyra
Amrix
Amtagvi
Amvuttra
amyl nitrite/sodium nitrite/sodium thiosulfate
Amzeeq
anacaulase topical
Anacin
Anafranil
anagrelide
anakinra
Analpram E
Analpram HC
AnaMantle HC
Anaphylm
Anaprox
Anaprox DS
Anascorp
Anaspaz
anastrozole
Anavip
Anbesol Maximum Strength
Ancef
Ancobon
Andembry (garadacimab-gxii)
Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo)
Androderm
AndroGel
Android
Androxy
Anectine
Angeliq
Angiomax
Angiomax RTU
angiotensin II
anidulafungin
anifrolumab
Anjeso
Anktiva (nogapendekin alfa inbakicept-pmln)
Annovera
Anoro Ellipta
Ansaid
ansuvimab
Antabuse
Antara
Anthim
Anthrasil
anthrax immune globulin (human)
anthrax vaccine
anthrax vaccine, adjuvanted
anti-inhibitor coagulant complex
anti-thymocyte globulin (rabbit)
antihemophilic factor (factor VIII, human)
antihemophilic factor (factor VIII, human)/von Willebrand factor ...
antihemophilic factor (factor VIII, recombinant)
antihemophilic factor (factor VIII, recombinant), Fc fusion prote...
antihemophilic factor (factor VIII, recombinant), glycopegylated
antihemophilic factor (factor VIII, recombinant), pegylated
antihemophilic factor (factor VIII, recombinant), porcine
antihemophilic factor (factor VIII, recombinant), single chain
antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein
antipyrine/benzocaine otic
antithrombin (recombinant)
antithrombin III
Antivert
Antizol
Anucort-HC
Anusol-HC Cream
Anusol-HC Suppository
Anzupgo
Apadaz
apalutamide
ApexiCon
ApexiCon E
Aphexda
Apidra
apitegromab
Apitegromab
apixaban
Aplenzin
Aplisol
Apokyn
apomorphine
Aponvie
apraclonidine ophthalmic
apremilast
aprepitant
Apresoline
Apretude
Apri
Apriso
aprocitentan
Aptensio XR
Aptiom
Aptivus
Aqneursa
Aquaphor
Aquaphor Baby Diaper Rash
Aquaphor Itch Relief
Aquasol A
Aquasol E
Aqvesme
Arakoda
Aralast NP
Aralen
Aranelle
Aranesp
Arava
Arazlo
Arbinoxa
Arbli
Arcalyst
Aredia
Arepanrix
Arexvy
arformoterol inhaled
argatroban
arginine
Aricept
Aricept ODT
Arikayce
Arimidex
arimoclomol
aripiprazole
aripiprazole bimonthly injection
aripiprazole lauroxil
aripiprazole monthly injection
Aristada
Aristada Initio
Arixtra
Armlupeg (pegfilgrastim-unne)
armodafinil
ArmonAir Digihaler
ArmonAir RespiClick
Armour Thyroid
Arnuity Ellipta
Aromasin
Arranon
arsenic trioxide
Artane
artemether/lumefantrine
artesunate
Arthriten
Arthritis Hot
Arthrotec
articaine/epinephrine
Arymo ER
Arynta
Arzerra
Asacol
Asacol HD
Asceniv (immune globulin human-slra)
asciminib
Ascor
ascorbic acid (vitamin C)
asenapine
asenapine transdermal
asfotase alfa
Ashlyna
Asmanex HFA
Asmanex Twisthaler
asparaginase
asparaginase Erwinia chrysanthemi
asparaginase erwinia chrysanthemi (recombinant)
Asparlas (calaspargase pegol-mknl)
Aspercreme
Aspercreme Arthritis Pain
Aspercreme Lidocaine 3 in 1 Foot Pain Relief Cream
Aspercreme Lidocaine Foot Pain Cream for Diabetic Skin
Aspercreme Lidocaine Pain Relief Cream
Aspercreme Lidocaine Pain Relief Liquid Roll-On
Aspercreme Lidocaine Pain Relief Patch
Aspercreme Lidocaine Pain Relief Spray
aspirin
aspirin/caffeine
aspirin/chlorpheniramine/dextromethorphan/phenylephrine
aspirin/chlorpheniramine/phenylephrine
aspirin/dextromethorphan/phenylephrine
aspirin/dipyridamole
aspirin/omeprazole
Aspruzyo Sprinkle
Astagraf XL
Astelin
Astepro Allergy
Asthmanefrin
Atacand
Atacand HCT
Atacicept
atacicept
Atarax
atazanavir
atazanavir/cobicistat
Atelvia
atenolol
atenolol/chlorthalidone
atezolizumab
atezolizumab/hyaluronidase
Atgam
atidarsagene autotemcel
Ativan
Atmeksi
atogepant
atoltivimab/maftivimab/odesivimab
atomoxetine
Atoncy
Atorvaliq
atorvastatin
atovaquone
atovaquone/proguanil
atracurium
Atralin
atrasentan
Atripla
AtroPen
atropine
atropine ophthalmic
atropine/pralidoxime
Atrovent HFA
Atrovent Nasal
ATryn
Attruby
Atzumi
Aubagio
Aubra EQ
Aucatzyl
Audenz
Augmentin
Augmentin ES-600
Augmentin XR
Augtyro
Aukelso (denosumab-kyqq)
Auralgan (original formulation)
auranofin
Aurlumyn
Aurovela 1.5/30
Aurovela 1/20
Aurovela 24 Fe
Aurovela Fe 1.5/30
Aurovela Fe 1/20
Auryxia
Austedo
Austedo XR
autologous mesenchymal stem cell-neurotrophic factor (MSC-NTF) ce...
Auvelity
Auvi-Q
avacincaptad pegol intravitreal
avacopan
Avage
avalglucosidase alfa
Avalide
avanafil
Avandaryl
Avandia
avapritinib
Avapro
Avasopasem
avasopasem
Avastin
avatrombopag
Aveed
Aveeno Anti-Itch Concentrated Lotion
Aveeno Baby Calming Comfort Lotion
Aveeno Baby Daily Moisture Cream
Aveeno Baby Daily Moisture Lotion
Aveeno Baby Eczema Therapy Moisturizing Cream
Aveeno Baby Eczema Therapy Nighttime Balm
Aveeno Baby Eczema Therapy Soothing Bath Treatment
Aveeno Calm + Restore Skin Therapy Balm
Aveeno Daily Moisturizing Lotion
Aveeno Eczema Therapy Moisturizing Cream
Aveeno Eczema Therapy Nighttime Itch Relief Balm
Aveeno Eczema Therapy Rescue Relief Treatment Gel Cream
Aveeno Hydrocortisone Anti-Itch Cream
Aveeno Positively Radiant Clear Complexion
Aveeno Skin Relief Hand Cream
Aveeno Skin Relief Moisturizing Lotion
Aveeno Skin Relief Overnight Cream
Aveeno Soothing Bath Treatment
Avelox
avelumab
Averi
Avgemsi
Aviane
Avidoxy
Avinza
Avita
Avlayah (tividenofusp alfa-eknm)
Avmapki Fakzynja Co-Pack
Avodart
Avonex
Avopef
Avsola (infliximab-axxq)
Avtozma (tocilizumab-anoh)
avutometinib and defactinib
Avycaz
Avzivi (bevacizumab-tnjn)
Awiqli (insulin icodec-abae)
axatilimab
Axert
axicabtagene ciloleucel
Axid
Axiron
axitinib
Axtle
Aygestin
Ayvakit
azacitidine
Azactam
Azasan
AzaSite
azathioprine
Azedra
azelaic acid topical
azelastine nasal
azelastine ophthalmic
azelastine/fluticasone propionate nasal
Azelex
Azilect
azilsartan medoxomil
azilsartan medoxomil/chlorthalidone
azithromycin
azithromycin ophthalmic
Azmacort
Azmiro
Azo Urinary Pain Relief
Azo Urinary Pain Relief Maximum Strength
Azopt
Azor
Azstarys
aztreonam
aztreonam inhaled
aztreonam/avibactam
Azulfidine
Azulfidine EN-tabs
Azurette

close

 

Select a medication above to begin.

Lifyorli

relacorilant

Drug Monograph

  • Black Box Warnings
  • Adult Dosing
  • Peds Dosing
  • Contraindications/Cautions
  • Drug Interactions
  • Adverse Reactions
  • Safety/Monitoring
  • Pregnancy/Lactation
  • Pharmacology
  • Formulary
  • Manufacturer/Pricing
  • Patient Education
  • Pill Pictures
  • Add to Interaction Check
  • Dosing Calculator

Adult Dosing .

Dosage forms:  CAP: 25 mg, 100 mg

Special Note

[uses, dosing may vary]
Info: refer to institution protocols and pkg insert prior to prescribing for uses and dosing including toxicity-related dose adjustments

ovarian CA, platinum-resistant

[150 mg PO qd on the day before, the day of, the day after each paclitaxel albumin-bound dose]
Info: for patients with epithelial ovarian, fallopian tube, or primary peritoneal CA who have received 1-3 lines of tx, including bevacizumab; give with food; do not open/crush/chew/dissolve cap

renal dosing

[see below]
CrCl >30: no adjustment; CrCl <30: not defined
HD/PD: not defined

hepatic dosing

[see below]
bilirubin >1.5x ULN: avoid use

Peds Dosing .

Peds dosing is currently unavailable or not applicable for this drug.

Contraindications / Cautions .

    com.epocrates.rxweb.beans.StringCollection@28d93683
  • hypersensitivity to drug or ingredient
  • glucocorticoid use, concurrent (life-threatening disease use)
  • bilirubin >1.5x ULN
  • avoid: breastfeeding during tx and x1wk after D/C
  • caution: patients of childbearing potential
  • caution: male patients of reproductive potential
  • caution: patients 65 yo and older
  • caution: surgery within 30 days
  • caution: stress
  • caution: illness, acute
  • caution: infection

Drug Interactions .

Overview

relacorilant

glucocorticoid antagonist

Interaction Characteristics:
  • CYP3A4 substrate
  • CYP3A4 inhibitor, strong
  • CYP2C8 inducer, weak
  • glucocorticoid antagonist
  • immunomodulatory effects
  • myelosuppressive oncologic agent

Contraindicated

  • adenovirus vaccine, live
  • Lifyorli (relacorilant)
    +
    adenovirus vaccine, live
    1 interaction

    Contraindicated

    relacorilant + adenovirus vaccine, live

    contraindicated; vaccinate at least 4wk before or 3mo after relacorilant use: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • alfuzosin
  • Lifyorli (relacorilant)
    +
    alfuzosin
    1 interaction

    Contraindicated

    relacorilant + alfuzosin

    contraindicated: combo may incr. alfuzosin levels, risk of QT prolongation, cardiac arrhythmias, hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited)

  • alprazolam
  • Lifyorli (relacorilant)
    +
    alprazolam
    1 interaction

    Contraindicated

    relacorilant + alprazolam

    contraindicated: combo may incr. alprazolam levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • BCG live intravesical
  • Lifyorli (relacorilant)
    +
    BCG live intravesical
    1 interaction

    Contraindicated

    relacorilant + BCG live intravesical

    contraindicated: combo may incr. risk of disseminated BCG infection; may decr. immune response (immunosuppressive effects)

  • betamethasone
  • Lifyorli (relacorilant)
    +
    betamethasone
    1 interaction

    Contraindicated

    relacorilant + betamethasone

    contraindicated if lifesaving corticosteroid use; otherwise, caution advised: combo may incr. betamethasone levels, risk of systemic corticosteroid effects incl. Cushing syndrome and adrenal suppression, serious infection; may decr. efficacy of both drugs (hepatic metabolism inhibited, additive effects; antagonistic effects)

  • chikungunya vaccine, live
  • Lifyorli (relacorilant)
    +
    chikungunya vaccine, live
    1 interaction

    Contraindicated

    relacorilant + chikungunya vaccine, live

    contraindicated; vaccinate at least 4wk before or 3mo after relacorilant use: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • cholera vaccine, live
  • Lifyorli (relacorilant)
    +
    cholera vaccine, live
    1 interaction

    Contraindicated

    relacorilant + cholera vaccine, live

    contraindicated; vaccinate at least 4wk before or 3mo after relacorilant use: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • ciclesonide
  • Lifyorli (relacorilant)
    +
    ciclesonide
    1 interaction

    Contraindicated

    relacorilant + ciclesonide

    contraindicated if lifesaving corticosteroid use; otherwise, caution advised: combo may incr. plasma ciclesonide exposure, risk of systemic corticosteroid effects incl. Cushing syndrome and adrenal suppression, serious infection; may decr. efficacy of both drugs (hepatic metabolism inhibited, additive effects; antagonistic effects)

  • cisapride
  • Lifyorli (relacorilant)
    +
    cisapride
    1 interaction

    Contraindicated

    relacorilant + cisapride

    contraindicated: combo may incr. cisapride levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • colchicine
  • Lifyorli (relacorilant)
    +
    colchicine
    1 interaction

    Contraindicated

    relacorilant + colchicine

    CV RISK REDUCTION: contraindicated; GOUT or FMF: contraindicated in pts w/ renal or hepatic impairment; otherwise, use alternative or decr. colchicine dose based on indication during and x14 days after relacorilant use as follows: GOUT PROPHYLAXIS: give colchicine 0.3 mg qod-qd; ACUTE GOUT TX: avoid combo if already receiving colchicine for gout prophylaxis; otherwise, give colchicine 0.6 mg x1, then 0.3 mg 1h later x1; FMF: decr. max colchicine dose to 0.6 mg/day divided qd-bid: combo may incr. colchicine levels, risk of myopathy, rhabdomyolysis, myelosuppression, other life-threatening toxicity (hepatic metabolism inhibited, additive effects)

  • conivaptan
  • Lifyorli (relacorilant)
    +
    conivaptan
    1 interaction

    Contraindicated

    relacorilant + conivaptan

    contraindicated: combo may incr. conivaptan levels, risk of overly rapid serum sodium correction, neurologic sequelae, other adverse effects (hepatic metabolism inhibited)

  • cortisone
  • Lifyorli (relacorilant)
    +
    cortisone
    1 interaction

    Contraindicated

    relacorilant + cortisone

    contraindicated if lifesaving corticosteroid use; otherwise, caution advised: combo may incr. cortisone levels, risk of systemic corticosteroid effects incl. Cushing syndrome and adrenal suppression, serious infection; may decr. efficacy of both drugs (hepatic metabolism inhibited, additive effects; antagonistic effects)

  • deflazacort
  • Lifyorli (relacorilant)
    +
    deflazacort
    1 interaction

    Contraindicated

    relacorilant + deflazacort

    contraindicated if lifesaving corticosteroid use; otherwise, caution advised: combo may incr. deflazacort active metabolite levels, risk of systemic corticosteroid effects incl. Cushing syndrome and adrenal suppression, serious infection; may decr. efficacy of both drugs (hepatic metabolism inhibited, additive effects; antagonistic effects)

  • dengue vaccine, live
  • Lifyorli (relacorilant)
    +
    dengue vaccine, live
    1 interaction

    Contraindicated

    relacorilant + dengue vaccine, live

    contraindicated; vaccinate at least 4wk before or 3mo after relacorilant use: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • dexamethasone
  • Lifyorli (relacorilant)
    +
    dexamethasone
    1 interaction

    Contraindicated

    relacorilant + dexamethasone

    contraindicated if lifesaving corticosteroid use; otherwise, caution advised: combo may incr. dexamethasone levels, risk of systemic corticosteroid effects incl. Cushing syndrome and adrenal suppression, serious infection, other adverse effects; may decr. efficacy of both drugs (hepatic metabolism inhibited, additive effects; antagonistic effects)

  • dihydroergotamine
  • Lifyorli (relacorilant)
    +
    dihydroergotamine
    1 interaction

    Contraindicated

    relacorilant + dihydroergotamine

    contraindicated: combo may incr. dihydroergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metabolism inhibited)

  • domperidone
  • Lifyorli (relacorilant)
    +
    domperidone
    1 interaction

    Contraindicated

    relacorilant + domperidone

    contraindicated: combo may incr. domperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • dronedarone
  • Lifyorli (relacorilant)
    +
    dronedarone
    1 interaction

    Contraindicated

    relacorilant + dronedarone

    contraindicated: combo may incr. dronedarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • eliglustat
  • Lifyorli (relacorilant)
    +
    eliglustat
    1 interaction

    Contraindicated

    relacorilant + eliglustat

    CYP2D6 EM: contraindicated if also combined w/ moderate or strong CYP2D6 inhibitor; otherwise, monitor ECG, decr. eliglustat dose to 84 mg qd; CYP2D6 IM or PM: contraindicated: combo may incr. eliglustat levels, risk of PR or QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • eplerenone
  • Lifyorli (relacorilant)
    +
    eplerenone
    1 interaction

    Contraindicated

    relacorilant + eplerenone

    contraindicated: combo may incr. eplerenone levels, risk of hyperkalemia, other adverse effects (hepatic metabolism inhibited)

  • ergotamine
  • Lifyorli (relacorilant)
    +
    ergotamine
    1 interaction

    Contraindicated

    relacorilant + ergotamine

    contraindicated: combo may incr. ergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metabolism inhibited)

  • finerenone
  • Lifyorli (relacorilant)
    +
    finerenone
    1 interaction

    Contraindicated

    relacorilant + finerenone

    contraindicated: combo may incr. finerenone levels, risk of hyperkalemia, other adverse effects (hepatic metabolism inhibited)

  • flibanserin
  • Lifyorli (relacorilant)
    +
    flibanserin
    1 interaction

    Contraindicated

    relacorilant + flibanserin

    contraindicated w/in 14 days prior to, during, and x2 days after flibanserin tx: combo may incr. flibanserin levels, risk of CNS depression, psychomotor impairment, severe hypotension (incl. syncope), other adverse effects (hepatic metabolism inhibited)

  • fludrocortisone
  • Lifyorli (relacorilant)
    +
    fludrocortisone
    1 interaction

    Contraindicated

    relacorilant + fludrocortisone

    contraindicated if lifesaving corticosteroid use; otherwise, caution advised: combo may incr. fludrocortisone levels, risk of systemic corticosteroid effects incl. Cushing syndrome and adrenal suppression, serious infection; may decr. efficacy of both drugs (hepatic metabolism inhibited, additive effects; antagonistic effects)

  • gepirone
  • Lifyorli (relacorilant)
    +
    gepirone
    1 interaction

    Contraindicated

    relacorilant + gepirone

    contraindicated: combo may incr. gepirone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • hydrocortisone
  • Lifyorli (relacorilant)
    +
    hydrocortisone
    1 interaction

    Contraindicated

    relacorilant + hydrocortisone

    contraindicated if lifesaving corticosteroid use; otherwise, caution advised: combo may incr. hydrocortisone levels, risk of systemic corticosteroid effects, incl. Cushing syndrome and adrenal suppression, serious infection, other adverse effects; may decr. efficacy of both drugs (hepatic metabolism inhibited, additive effects; antagonistic effects)

  • influenza nasal vaccine, live
  • Lifyorli (relacorilant)
    +
    influenza nasal vaccine, live
    1 interaction

    Contraindicated

    relacorilant + influenza nasal vaccine, live

    contraindicated; vaccinate at least 4wk before or 3mo after relacorilant use: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • isavuconazonium
  • Lifyorli (relacorilant)
    +
    isavuconazonium
    1 interaction

    Contraindicated

    relacorilant + isavuconazonium

    contraindicated: combo may incr. isavuconazole levels, risk of adverse effects (hepatic metabolism inhibited)

  • ivabradine
  • Lifyorli (relacorilant)
    +
    ivabradine
    1 interaction

    Contraindicated

    relacorilant + ivabradine

    contraindicated: combo may incr. ivabradine levels, risk of bradycardia, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • lomitapide
  • Lifyorli (relacorilant)
    +
    lomitapide
    1 interaction

    Contraindicated

    relacorilant + lomitapide

    contraindicated: combo may incr. lomitapide levels, risk of hepatotoxicity, other adverse effects (hepatic metabolism inhibited)

  • lonafarnib
  • Lifyorli (relacorilant)
    +
    lonafarnib
    1 interaction

    Contraindicated

    relacorilant + lonafarnib

    contraindicated: combo may incr. lonafarnib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

  • lovastatin
  • Lifyorli (relacorilant)
    +
    lovastatin
    1 interaction

    Contraindicated

    relacorilant + lovastatin

    contraindicated: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited)

  • lurasidone
  • Lifyorli (relacorilant)
    +
    lurasidone
    1 interaction

    Contraindicated

    relacorilant + lurasidone

    contraindicated: combo may incr. lurasidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • measles/mumps/rubella vaccine, live
  • Lifyorli (relacorilant)
    +
    measles/ mumps/ rubella vaccine, live
    1 interaction

    Contraindicated

    relacorilant + measles/ mumps/ rubella vaccine, live

    contraindicated; vaccinate at least 4wk before or 3mo after relacorilant use: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • methylprednisolone
  • Lifyorli (relacorilant)
    +
    methylprednisolone
    1 interaction

    Contraindicated

    relacorilant + methylprednisolone

    contraindicated if lifesaving corticosteroid use; otherwise, caution advised: combo may incr. methylprednisolone levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection; may decr. efficacy of both drugs (hepatic metabolism inhibited, additive effects; antagonistic effects)

  • naloxegol
  • Lifyorli (relacorilant)
    +
    naloxegol
    1 interaction

    Contraindicated

    relacorilant + naloxegol

    contraindicated: combo may incr. naloxegol levels, risk of adverse effects (hepatic metabolism inhibited)

  • pacritinib
  • Lifyorli (relacorilant)
    +
    pacritinib
    1 interaction

    Contraindicated

    relacorilant + pacritinib

    contraindicated: combo may incr. pacritinib levels, risk of QT prolongation, cardiac arrhythmias, serious infection, myelosuppression, bleeding (incl. life-threatening), other adverse effects; may decr. relacorilant levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism possibly induced)

  • pimozide
  • Lifyorli (relacorilant)
    +
    pimozide
    1 interaction

    Contraindicated

    relacorilant + pimozide

    contraindicated: combo may incr. pimozide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • prednisolone
  • Lifyorli (relacorilant)
    +
    prednisolone
    1 interaction

    Contraindicated

    relacorilant + prednisolone

    contraindicated if lifesaving corticosteroid use; otherwise, caution advised: combo may incr. prednisolone levels, risk of systemic corticosteroid effects, including Cushing syndrome and adrenal suppression, serious infection, other adverse effects; may decr. efficacy of both drugs (hepatic metabolism inhibited, additive effects; antagonistic effects)

  • prednisone
  • Lifyorli (relacorilant)
    +
    prednisone
    1 interaction

    Contraindicated

    relacorilant + prednisone

    contraindicated if lifesaving corticosteroid use; otherwise, caution advised: combo may incr. prednisone levels, risk of systemic corticosteroid effects, including Cushing syndrome and adrenal suppression, serious infection, other adverse effects; may decr. efficacy of both drugs (hepatic metabolism inhibited, additive effects; antagonistic effects)

  • ranolazine
  • Lifyorli (relacorilant)
    +
    ranolazine
    1 interaction

    Contraindicated

    relacorilant + ranolazine

    contraindicated: combo may incr. ranolazine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • rotavirus vaccine, live
  • Lifyorli (relacorilant)
    +
    rotavirus vaccine, live
    1 interaction

    Contraindicated

    relacorilant + rotavirus vaccine, live

    contraindicated; vaccinate at least 4wk before or 3mo after relacorilant use: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • silodosin
  • Lifyorli (relacorilant)
    +
    silodosin
    1 interaction

    Contraindicated

    relacorilant + silodosin

    contraindicated: combo may incr. silodosin levels, risk of adverse effects (hepatic metabolism inhibited)

  • simvastatin
  • Lifyorli (relacorilant)
    +
    simvastatin
    1 interaction

    Contraindicated

    relacorilant + simvastatin

    contraindicated: combo may incr. simvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited)

  • smallpox vaccine, live
  • Lifyorli (relacorilant)
    +
    smallpox vaccine, live
    1 interaction

    Contraindicated

    relacorilant + smallpox vaccine, live

    contraindicated; vaccinate at least 4wk before or 3mo after relacorilant use: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • suzetrigine
  • Lifyorli (relacorilant)
    +
    suzetrigine
    1 interaction

    Contraindicated

    relacorilant + suzetrigine

    contraindicated: combo may incr. suzetrigine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

  • talimogene laherparepvec
  • Lifyorli (relacorilant)
    +
    talimogene laherparepvec
    1 interaction

    Contraindicated

    relacorilant + talimogene laherparepvec

    contraindicated: combo may incr. risk of disseminated herpetic infection; may decr. immune response (immunosuppressive effects)

  • tolvaptan
  • Lifyorli (relacorilant)
    +
    tolvaptan
    1 interaction

    Contraindicated

    relacorilant + tolvaptan

    contraindicated: combo may incr. tolvaptan levels, risk of adverse effects (hepatic metabolism inhibited)

  • triamcinolone
  • Lifyorli (relacorilant)
    +
    triamcinolone
    1 interaction

    Contraindicated

    relacorilant + triamcinolone

    contraindicated if lifesaving corticosteroid use; otherwise, caution advised: combo may incr. triamcinolone levels, risk of systemic corticosteroid effects incl. Cushing syndrome and adrenal suppression, serious infection; may decr. efficacy of both drugs (hepatic metabolism inhibited, additive effects; antagonistic effects)

  • triazolam
  • Lifyorli (relacorilant)
    +
    triazolam
    1 interaction

    Contraindicated

    relacorilant + triazolam

    contraindicated: combo may incr. triazolam levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • typhoid vaccine, live
  • Lifyorli (relacorilant)
    +
    typhoid vaccine, live
    1 interaction

    Contraindicated

    relacorilant + typhoid vaccine, live

    contraindicated; vaccinate at least 4wk before or 3mo after relacorilant use: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • ubrogepant
  • Lifyorli (relacorilant)
    +
    ubrogepant
    1 interaction

    Contraindicated

    relacorilant + ubrogepant

    contraindicated: combo may incr. ubrogepant levels, risk of adverse effects (hepatic metabolism inhibited)

  • varicella vaccine, live
  • Lifyorli (relacorilant)
    +
    varicella vaccine, live
    1 interaction

    Contraindicated

    relacorilant + varicella vaccine, live

    contraindicated; vaccinate at least 4wk before or 3mo after relacorilant use: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

  • venetoclax
  • Lifyorli (relacorilant)
    +
    venetoclax
    1 interaction

    Contraindicated

    relacorilant + venetoclax

    monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: contraindicated during venetoclax ramp-up phases; if on stable tx, consider alternative or decr. venetoclax dose to 100 mg/day; AML: ramp-up venetoclax dose as follows: 10 mg/day on Day 1, 20 mg/day on Day 2, 50 mg/day on Day 3, 100 mg/day on Day 4 and beyond; if on stable AML tx, decr. venetoclax dose to 100 mg/day: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, additive effects)

  • voclosporin
  • Lifyorli (relacorilant)
    +
    voclosporin
    1 interaction

    Contraindicated

    relacorilant + voclosporin

    contraindicated: combo may incr. voclosporin levels, risk of QT prolongation, cardiac arrhythmias, serious infection, nephrotoxicity, other adverse effects (hepatic metabolism inhibited, additive effects)

  • yellow fever vaccine, live
  • Lifyorli (relacorilant)
    +
    yellow fever vaccine, live
    1 interaction

    Contraindicated

    relacorilant + yellow fever vaccine, live

    contraindicated; vaccinate at least 4wk before or 3mo after relacorilant use: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

Avoid/Use Alternative

  • acalabrutinib
  • Lifyorli (relacorilant)
    +
    acalabrutinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + acalabrutinib

    avoid combo or hold acalabrutinib if relacorilant use <7 days: combo may incr. acalabrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

  • adagrasib
  • Lifyorli (relacorilant)
    +
    adagrasib
    1 interaction

    Avoid/Use Alternative

    relacorilant + adagrasib

    avoid combo until adagrasib at steady state (approx. 8 days): combo may incr. adagrasib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • ado-trastuzumab emtansine
  • Lifyorli (relacorilant)
    +
    ado-trastuzumab emtansine
    1 interaction

    Avoid/Use Alternative

    relacorilant + ado-trastuzumab emtansine

    avoid combo during relacorilant use; may start/restart ado-trastuzumab emtansine after relacorilant cleared (approx. 3 inhibitor half-lives): combo may incr. small molecule cytotoxin (DM1) levels, risk of myelosuppression, hepatotoxicity, cardiotoxicity, other adverse effects (hepatic metabolism inhibited)

  • alfentanil
  • Lifyorli (relacorilant)
    +
    alfentanil
    1 interaction

    Avoid/Use Alternative

    relacorilant + alfentanil

    use alternative or monitor respiratory rate; consider decr. alfentanil dose: combo may incr. alfentanil levels, risk of CNS and respiratory depression, psychomotor impairment, delayed recovery from anesthesia, other adverse effects (hepatic metabolism inhibited)

  • almotriptan
  • Lifyorli (relacorilant)
    +
    almotriptan
    1 interaction

    Avoid/Use Alternative

    relacorilant + almotriptan

    limit almotriptan start dose to 6.25 mg PO x1, max 12.5 mg/24h; avoid combo if concomitant renal or hepatic impairment: combo may incr. almotriptan levels, risk of adverse effects (hepatic metabolism inhibited)

  • amiodarone
  • Lifyorli (relacorilant)
    +
    amiodarone
    1 interaction

    Avoid/Use Alternative

    relacorilant + amiodarone

    use alternative or monitor ECG: combo may incr. or decr. amiodarone levels, incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (hepatic metabolism altered)

  • apalutamide
  • Lifyorli (relacorilant)
    +
    apalutamide
    1 interaction

    Avoid/Use Alternative

    relacorilant + apalutamide

    avoid combo: combo may incr. apalutamide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. relacorilant levels, efficacy (hepatic metabolism inhibited; hepatic metabolism possibly induced)

  • apixaban
  • Lifyorli (relacorilant)
    +
    apixaban
    1 interaction

    Avoid/Use Alternative

    relacorilant + apixaban

    ADULT PTS: monitor bleeding s/sx; if also combined w/ P-gp inhibitor, decr. apixaban 5 mg bid or 10 mg bid dose by 50% or avoid combo if already on 2.5 mg bid; PEDS PTS: monitor bleeding s/sx; if also combined w/ P-gp inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metabolism inhibited)

  • aprepitant
  • Lifyorli (relacorilant)
    +
    aprepitant
    1 interaction

    Avoid/Use Alternative

    relacorilant + aprepitant

    avoid combo: combo may incr. aprepitant levels, risk of adverse effects (hepatic metabolism inhibited)

  • aripiprazole bimonthly injection
  • Lifyorli (relacorilant)
    +
    aripiprazole bimonthly injection
    1 interaction

    Avoid/Use Alternative

    relacorilant + aripiprazole bimonthly injection

    for concurrent use >14 days, decr. aripiprazole dose to 720 mg q2mo; if also CYP2D6 PM or if also combined w/ strong CYP2D6 inhibitor, avoid combo: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

  • aripiprazole lauroxil
  • Lifyorli (relacorilant)
    +
    aripiprazole lauroxil
    1 interaction

    Avoid/Use Alternative

    relacorilant + aripiprazole lauroxil

    ARISTADA INITIO: avoid combo; ARISTADA: if concurrent use >14 days, decr. aripiprazole lauroxil 1064 mg q2mo to 441 mg qmo, 882 mg q6wk to 441 mg qmo, 882 mg qmo to 662 mg qmo, 662 mg qmo to 441 mg qmo; if also CYP2D6 PM, decr. 1064 mg q2mo to 441 mg qmo, 882 mg qmo or q6wk to 441 mg qmo, 662 mg qmo to 441 mg qmo; if also combined w/ strong CYP2D6 inhibitor, avoid combo w/ 1064 mg, 882 mg, or 662 mg doses; no dose adjustment if on 441 mg dose: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

  • aripiprazole monthly injection
  • Lifyorli (relacorilant)
    +
    aripiprazole monthly injection
    1 interaction

    Avoid/Use Alternative

    relacorilant + aripiprazole monthly injection

    1-DAY START REGIMEN: for concurrent use >14 days, decr. IM aripiprazole 400 mg dose to 300 mg; if also CYP2D6 PM or if also combined w/ strong CYP2D6 inhibitor, avoid combo; 14-DAY START REGIMEN: for concurrent use >14 days, decr. IM aripiprazole 400 mg dose to 300 mg or decr. 300 mg dose to 200 mg; if also CYP2D6 PM, decr. IM aripiprazole dose to 200 mg; if also combined w/ strong CYP2D6 inhibitor, decr. IM aripiprazole 400 mg dose to 200 mg and decr. 300 mg dose to 160 mg: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

  • avanafil
  • Lifyorli (relacorilant)
    +
    avanafil
    1 interaction

    Avoid/Use Alternative

    relacorilant + avanafil

    avoid combo: combo may incr. avanafil levels, risk of hypotension, priapism, other adverse effects (hepatic metabolism inhibited)

  • avapritinib
  • Lifyorli (relacorilant)
    +
    avapritinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + avapritinib

    avoid combo: combo may incr. avapritinib levels, risk of bleeding (incl. life-threatening), other adverse effects (hepatic metabolism inhibited)

  • axitinib
  • Lifyorli (relacorilant)
    +
    axitinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + axitinib

    use alternative or decr. axitinib dose approx. 50%: combo may incr. axitinib levels, risk of adverse effects (hepatic metabolism inhibited)

  • bosentan
  • Lifyorli (relacorilant)
    +
    bosentan
    1 interaction

    Avoid/Use Alternative

    relacorilant + bosentan

    avoid combo if also combined w/ CYP2C9 inhibitor; otherwise caution advised: combo may incr. bosentan levels, risk of adverse effects; may decr. relacorilant levels, efficacy (hepatic metabolism inhibited; hepatic metabolism possibly induced)

  • bosutinib
  • Lifyorli (relacorilant)
    +
    bosutinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + bosutinib

    avoid combo: combo may incr. bosutinib levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • brigatinib
  • Lifyorli (relacorilant)
    +
    brigatinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + brigatinib

    use alternative or monitor BP, HR; decr. brigatinib dose by approx. 50% as follows: if taking 180 mg, decr. to 90 mg; if taking 90 mg, decr. to 60 mg: combo may incr. brigatinib levels, risk of HTN, bradycardia, other adverse effects (hepatic metabolism inhibited)

  • bromocriptine
  • Lifyorli (relacorilant)
    +
    bromocriptine
    1 interaction

    Avoid/Use Alternative

    relacorilant + bromocriptine

    avoid combo if diabetes tx; otherwise, consider decr. bromocriptine dose: combo may incr. bromocriptine levels, risk of adverse effects (hepatic metabolism inhibited)

  • budesonide
  • Lifyorli (relacorilant)
    +
    budesonide
    1 interaction

    Avoid/Use Alternative

    relacorilant + budesonide

    avoid combo: combo may incr. budesonide levels, risk of systemic corticosteroid effects, incl. Cushing syndrome, adrenal suppression, serious infection, other adverse effects; may decr. efficacy of both drugs (hepatic metabolism inhibited, additive effects; antagonistic effects)

  • budesonide rectal
  • Lifyorli (relacorilant)
    +
    budesonide rectal
    1 interaction

    Avoid/Use Alternative

    relacorilant + budesonide rectal

    avoid combo: combo may incr. budesonide levels, risk of systemic corticosteroid effects incl. Cushing syndrome and adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited, additive effects)

  • buprenorphine
  • Lifyorli (relacorilant)
    +
    buprenorphine
    1 interaction

    Avoid/Use Alternative

    relacorilant + buprenorphine

    use alternative or monitor respiratory rate, ECG; consider decr. buprenorphine dose: combo may incr. buprenorphine levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • buspirone
  • Lifyorli (relacorilant)
    +
    buspirone
    1 interaction

    Avoid/Use Alternative

    relacorilant + buspirone

    consider alternative or restart buspirone dose at 2.5 mg qd: combo may incr. buspirone levels, risk of adverse effects (hepatic metabolism inhibited)

  • butalbital
  • Lifyorli (relacorilant)
    +
    butalbital
    1 interaction

    Avoid/Use Alternative

    relacorilant + butalbital

    avoid combo: combo may decr. relacorilant levels, efficacy (hepatic metabolism possibly induced)

  • cabazitaxel
  • Lifyorli (relacorilant)
    +
    cabazitaxel
    1 interaction

    Avoid/Use Alternative

    relacorilant + cabazitaxel

    use alternative or consider decr. cabazitaxel dose 25%; monitor CBC: combo may incr. cabazitaxel levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

  • cabozantinib
  • Lifyorli (relacorilant)
    +
    cabozantinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + cabozantinib

    use alternative or monitor ECG, BP, bleeding s/sx; decr. cabozantinib daily dose by 40 mg if medullary thyroid CA use or decr. by 20 mg if renal cell CA, hepatocellular CA, differentiated thyroid CA, or NET use: combo may incr. cabozantinib levels, risk of QT prolongation, cardiac arrhythmias, HTN, GI or other bleeding (incl. life-threatening), other adverse effects (hepatic metabolism inhibited)

  • capivasertib
  • Lifyorli (relacorilant)
    +
    capivasertib
    1 interaction

    Avoid/Use Alternative

    relacorilant + capivasertib

    use alternative or monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

  • carbamazepine
  • Lifyorli (relacorilant)
    +
    carbamazepine
    1 interaction

    Avoid/Use Alternative

    relacorilant + carbamazepine

    avoid combo: combo may incr. carbamazepine levels, risk of adverse effects; may decr. relacorilant levels, efficacy (hepatic metabolism inhibited; hepatic metabolism possibly induced)

  • cariprazine
  • Lifyorli (relacorilant)
    +
    cariprazine
    1 interaction

    Avoid/Use Alternative

    relacorilant + cariprazine

    IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.5 mg qd, then may incr. to 0.75 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.5 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING RELACORILANT: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.5 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 0.75 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

  • ceritinib
  • Lifyorli (relacorilant)
    +
    ceritinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + ceritinib

    use alternative or decr. ceritinib dose 33%; monitor ECG, electrolytes: combo may incr. ceritinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • chloramphenicol
  • Lifyorli (relacorilant)
    +
    chloramphenicol
    1 interaction

    Avoid/Use Alternative

    relacorilant + chloramphenicol

    use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • cladribine oral
  • Lifyorli (relacorilant)
    +
    cladribine oral
    1 interaction

    Avoid/Use Alternative

    relacorilant + cladribine oral

    avoid combo: combo may incr. risk of serious infection, myelosuppression (additive effects)

  • cobimetinib
  • Lifyorli (relacorilant)
    +
    cobimetinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + cobimetinib

    avoid combo: combo may incr. cobimetinib levels, risk of adverse effects (hepatic metabolism inhibited)

  • codeine
  • Lifyorli (relacorilant)
    +
    codeine
    1 interaction

    Avoid/Use Alternative

    relacorilant + codeine

    use alternative or monitor resp. rate, consider decr. codeine dose: combo may incr. codeine and active metabolite morphine levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, may incr. production of active metabolite morphine)

  • copanlisib
  • Lifyorli (relacorilant)
    +
    copanlisib
    1 interaction

    Avoid/Use Alternative

    relacorilant + copanlisib

    use alternative or decr. copanlisib dose to 45 mg; monitor CBC: combo may incr. copanlisib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

  • crizotinib
  • Lifyorli (relacorilant)
    +
    crizotinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + crizotinib

    use alternative or monitor ECG, electrolytes, CBC and adjust crizotinib dose; Adults w/ NSCLC, IMT: decr. crizotinib dose to 250 mg qd; Peds w/ IMT or Adult/Peds w/ ALCL: decr. crizotinib dose as follows: 70 mg bid if BSA 0.38-0.46 m^2; 80 mg bid if BSA 0.47-0.51 m^2; 90 mg bid if BSA 0.52-0.61 m^2; 120 mg bid if BSA 0.62-0.8 m^2; 150 mg bid if BSA 0.81-0.97 m^2; 170 mg bid if BSA 0.98-1.16 m^2; 200 mg bid if BSA 1.17-1.69 m^2; 250 mg bid if BSA 1.7 m^2 or greater: combo may incr. crizotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • dabrafenib
  • Lifyorli (relacorilant)
    +
    dabrafenib
    1 interaction

    Avoid/Use Alternative

    relacorilant + dabrafenib

    use alternative: combo may incr. dabrafenib levels, risk of adverse effects; may decr. relacorilant levels, efficacy (hepatic metabolism inhibited; hepatic metabolism possibly induced)

  • daridorexant
  • Lifyorli (relacorilant)
    +
    daridorexant
    1 interaction

    Avoid/Use Alternative

    relacorilant + daridorexant

    avoid combo: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • dasatinib
  • Lifyorli (relacorilant)
    +
    dasatinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + dasatinib

    use alternative or monitor ECG, CBC; consider decr. dasatinib dose as follows: if taking dasatinib 140 mg/day, decr. dose to 40 mg/day; if taking dasatinib 70-100 mg/day, decr. dose to 20 mg/day; if taking dasatinib 40-60 mg/day, consider holding dasatinib during and x1wk after relacorilant use: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • defactinib
  • Lifyorli (relacorilant)
    +
    defactinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + defactinib

    avoid combo: combo may incr. defactinib levels, risk of adverse effects (hepatic metabolism inhibited)

  • deferiprone
  • Lifyorli (relacorilant)
    +
    deferiprone
    1 interaction

    Avoid/Use Alternative

    relacorilant + deferiprone

    use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • dexrazoxane
  • Lifyorli (relacorilant)
    +
    dexrazoxane
    1 interaction

    Avoid/Use Alternative

    relacorilant + dexrazoxane

    monitor CBC if anthracycline extravasation or doxorubicin cardioprotective use; otherwise, avoid combo: combo may incr. risk of myelosuppression; may decr. efficacy of cancer chemo (additive effects; mechanism unknown)

  • dihydrocodeine
  • Lifyorli (relacorilant)
    +
    dihydrocodeine
    1 interaction

    Avoid/Use Alternative

    relacorilant + dihydrocodeine

    use alternative or monitor respiratory rate; consider decr. dihydrocodeine dose: combo may incr. dihydrocodeine and active metabolite dihydromorphine levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, may increase production of active metabolite dihydromorphine)

  • disopyramide
  • Lifyorli (relacorilant)
    +
    disopyramide
    1 interaction

    Avoid/Use Alternative

    relacorilant + disopyramide

    use alternative or monitor disopyramide levels, ECG: combo may incr. disopyramide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • docetaxel
  • Lifyorli (relacorilant)
    +
    docetaxel
    1 interaction

    Avoid/Use Alternative

    relacorilant + docetaxel

    use alternative or monitor CBC; consider decr. docetaxel dose 50%: combo may incr. docetaxel levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

  • dordaviprone
  • Lifyorli (relacorilant)
    +
    dordaviprone
    1 interaction

    Avoid/Use Alternative

    relacorilant + dordaviprone

    use alternative or monitor ECG; for adult and pediatric patients weighing at least 52.5 kg, decr. dordaviprone dose to 375 mg once weekly; dose recommendation not established in pediatric patients weighing less than 52.5 kg: combo may incr. dordaviprone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • doxorubicin
  • Lifyorli (relacorilant)
    +
    doxorubicin
    1 interaction

    Avoid/Use Alternative

    relacorilant + doxorubicin

    avoid combo: combo may incr. doxorubicin levels, risk serious infection, myelosuppression, cardiotoxicity, other adverse effects (hepatic metabolism inhibited, additive effects)

  • duvelisib
  • Lifyorli (relacorilant)
    +
    duvelisib
    1 interaction

    Avoid/Use Alternative

    relacorilant + duvelisib

    use alternative or decr. duvelisib dose to 15 mg: combo may incr. duvelisib levels, risk of serious infection, other adverse effects (hepatic metabolism inhibited, additive effects)

  • elacestrant
  • Lifyorli (relacorilant)
    +
    elacestrant
    1 interaction

    Avoid/Use Alternative

    relacorilant + elacestrant

    avoid combo: combo may incr. elacestrant levels, risk of adverse effects (hepatic metabolism inhibited)

  • elagolix
  • Lifyorli (relacorilant)
    +
    elagolix
    1 interaction

    Avoid/Use Alternative

    relacorilant + elagolix

    avoid combo if elagolix 300 mg bid regimen; limit elagolix use x1mo if 200 mg bid regimen; limit elagolix use x6mo if 150 mg qd regimen: combo may incr. elagolix levels, risk of adverse effects (hepatic metabolism inhibited)

  • elbasvir
  • Lifyorli (relacorilant)
    +
    elbasvir
    1 interaction

    Avoid/Use Alternative

    relacorilant + elbasvir

    avoid combo: combo may incr. elbasvir levels, risk of adverse effects (hepatic metabolism inhibited)

  • eletriptan
  • Lifyorli (relacorilant)
    +
    eletriptan
    1 interaction

    Avoid/Use Alternative

    relacorilant + eletriptan

    avoid combo: combo may incr. eletriptan levels, risk of adverse effects (hepatic metabolism inhibited)

  • elinzanetant
  • Lifyorli (relacorilant)
    +
    elinzanetant
    1 interaction

    Avoid/Use Alternative

    relacorilant + elinzanetant

    avoid combo: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • encorafenib
  • Lifyorli (relacorilant)
    +
    encorafenib
    1 interaction

    Avoid/Use Alternative

    relacorilant + encorafenib

    avoid combo: combo may incr. encorafenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. relacorilant levels, efficacy (hepatic metabolism inhibited; hepatic metabolism possibly induced)

  • ensartinib
  • Lifyorli (relacorilant)
    +
    ensartinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + ensartinib

    avoid combo: combo may incr. ensartinib levels, risk of bradycardia, hyperglycemia, other adverse effects (hepatic metabolism possibly inhibited)

  • entrectinib
  • Lifyorli (relacorilant)
    +
    entrectinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + entrectinib

    PEDS PATIENTS with ENTRECTINIB START DOSE <200 mg/day: avoid combo; ADULT AND PEDS PATIENTS >2yo: use alternative or monitor ECG, CBC, limit coadmin. to 14 days or less and decr. entrectinib dose as follows: if entrectinib start dose 200 mg qd, decr. to 50 mg qod; if entrectinib start dose 300 or 400 mg qd, decr. to 50 mg qd; if entrectinib start dose 600 mg qd, decr. to 100 mg qd: combo may incr. entrectinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • enzalutamide
  • Lifyorli (relacorilant)
    +
    enzalutamide
    1 interaction

    Avoid/Use Alternative

    relacorilant + enzalutamide

    avoid combo: combo may decr. relacorilant levels, efficacy (hepatic metabolism possibly induced)

  • erdafitinib
  • Lifyorli (relacorilant)
    +
    erdafitinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + erdafitinib

    use alternative or monitor phosphate: combo may incr. erdafitinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metabolism inhibited)

  • erlotinib
  • Lifyorli (relacorilant)
    +
    erlotinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + erlotinib

    use alternative or consider decr. erlotinib dose by 50 mg/day decrements: combo may incr. erlotinib levels, risk of adverse effects (hepatic metabolism inhibited)

  • estazolam
  • Lifyorli (relacorilant)
    +
    estazolam
    1 interaction

    Avoid/Use Alternative

    relacorilant + estazolam

    use alternative or monitor respiratory rate; consider decr. estazolam dose: combo may incr. estazolam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • ethinyl estradiol (contraceptive)
  • Lifyorli (relacorilant)
    +
    ethinyl estradiol (contraceptive)
    1 interaction

    Avoid/Use Alternative

    relacorilant + ethinyl estradiol (contraceptive)

    use additional non-hormonal or alternative contraception during and x28 days after relacorilant use; monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may decr. ethinyl estradiol levels, contraceptive efficacy; may initially incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism induced; hepatic metabolism inhibited)

  • etoposide
  • Lifyorli (relacorilant)
    +
    etoposide
    1 interaction

    Avoid/Use Alternative

    relacorilant + etoposide

    use alternative or monitor CBC: combo may incr. etoposide levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

  • etrasimod
  • Lifyorli (relacorilant)
    +
    etrasimod
    1 interaction

    Avoid/Use Alternative

    relacorilant + etrasimod

    avoid combo during and x5wk after etrasimod tx: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metabolism inhibited, additive effects)

  • everolimus
  • Lifyorli (relacorilant)
    +
    everolimus
    1 interaction

    Avoid/Use Alternative

    relacorilant + everolimus

    admin. PCP prophylaxis; BREAST CA, PNET, RENAL CELL CA, or RENAL ANGIOMYOLIPOMA: if also combined w/ P-gp inhibitor, avoid combo; otherwise, monitor CBC; TSC-ASSOC. SEGA or TSC-ASSOC. PARTIAL-ONSET SEIZURES: if also combined w/ P-gp inhibitor, avoid combo; otherwise, monitor everolimus levels, CBC; TRANSPLANT: use alternative or monitor everolimus levels, CBC: combo may incr. everolimus levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

  • fedratinib
  • Lifyorli (relacorilant)
    +
    fedratinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + fedratinib

    consider alternative or monitor CBC, LFTs and decr. fedratinib dose to 200 mg qd: combo may incr. fedratinib levels, risk myelosuppression, hepatotoxicity, other adverse effects (hepatic metabolism inhibited)

  • fentanyl
  • Lifyorli (relacorilant)
    +
    fentanyl
    1 interaction

    Avoid/Use Alternative

    relacorilant + fentanyl

    use alternative or monitor resp. rate, consider decr. fentanyl dose: combo may incr. fentanyl levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • fesoterodine
  • Lifyorli (relacorilant)
    +
    fesoterodine
    1 interaction

    Avoid/Use Alternative

    relacorilant + fesoterodine

    avoid combo in peds pts <35 kg; adjust max fesoterodine dose to 4 mg/day in adults and peds pts >35 kg: combo may incr. fesoterodine active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

  • fexinidazole
  • Lifyorli (relacorilant)
    +
    fexinidazole
    1 interaction

    Avoid/Use Alternative

    relacorilant + fexinidazole

    use alternative: combo may decr. fexinidazole active metabolite levels, efficacy; may decr. relacorilant levels, efficacy; may incr. risk of myelosuppression (hepatic metabolism inhibited, decr. conversion to active metabolites; hepatic metabolism possibly induced; additive effects)

  • fluticasone propionate
  • Lifyorli (relacorilant)
    +
    fluticasone propionate
    1 interaction

    Avoid/Use Alternative

    relacorilant + fluticasone propionate

    avoid combo: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects, incl. Cushing syndrome, adrenal suppression, serious infection (hepatic metabolism inhibited, additive effects)

  • fosaprepitant
  • Lifyorli (relacorilant)
    +
    fosaprepitant
    1 interaction

    Avoid/Use Alternative

    relacorilant + fosaprepitant

    avoid combo: combo may incr. aprepitant levels, risk of adverse effects (hepatic metabolism inhibited)

  • fosphenytoin
  • Lifyorli (relacorilant)
    +
    fosphenytoin
    1 interaction

    Avoid/Use Alternative

    relacorilant + fosphenytoin

    avoid combo: combo may decr. relacorilant levels, efficacy (hepatic metabolism possibly induced)

  • futibatinib
  • Lifyorli (relacorilant)
    +
    futibatinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + futibatinib

    avoid combo: combo may incr. futibatinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metabolism inhibited)

  • ganciclovir
  • Lifyorli (relacorilant)
    +
    ganciclovir
    1 interaction

    Avoid/Use Alternative

    relacorilant + ganciclovir

    use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • gepotidacin
  • Lifyorli (relacorilant)
    +
    gepotidacin
    1 interaction

    Avoid/Use Alternative

    relacorilant + gepotidacin

    use alternative or monitor ECG, electrolytes: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • gilteritinib
  • Lifyorli (relacorilant)
    +
    gilteritinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + gilteritinib

    consider alternative or monitor ECG: combo may incr. gilteritinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • glasdegib
  • Lifyorli (relacorilant)
    +
    glasdegib
    1 interaction

    Avoid/Use Alternative

    relacorilant + glasdegib

    consider alternative or monitor CBC, ECG: combo may incr. glasdegib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • grazoprevir
  • Lifyorli (relacorilant)
    +
    grazoprevir
    1 interaction

    Avoid/Use Alternative

    relacorilant + grazoprevir

    avoid combo: combo may incr. grazoprevir levels, risk of adverse effects (hepatic metabolism inhibited)

  • hydrocodone
  • Lifyorli (relacorilant)
    +
    hydrocodone
    1 interaction

    Avoid/Use Alternative

    relacorilant + hydrocodone

    use alternative or monitor resp. rate, ECG, consider decr. (benz)hydrocodone dose: combo may incr. hydrocodone levels, risk of CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • ibrutinib
  • Lifyorli (relacorilant)
    +
    ibrutinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + ibrutinib

    avoid combo or hold ibrutinib if relacorilant tx <7 days: combo may incr. ibrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

  • idelalisib
  • Lifyorli (relacorilant)
    +
    idelalisib
    1 interaction

    Avoid/Use Alternative

    relacorilant + idelalisib

    use alternative or monitor LFTs, CBC, GI toxicity sx: combo may incr. idelalisib levels, risk of hepatotoxicity, serious infection, myelosuppression, GI toxicity, pneumonitis, other adverse effects (hepatic metabolism inhibited, additive effects)

  • imlunestrant
  • Lifyorli (relacorilant)
    +
    imlunestrant
    1 interaction

    Avoid/Use Alternative

    relacorilant + imlunestrant

    use alternative or decr. imlunestrant dose to 200 mg once daily: combo may incr. imlunestrant levels, risk of adverse effects (hepatic metabolism inhibited)

  • irinotecan
  • Lifyorli (relacorilant)
    +
    irinotecan
    1 interaction

    Avoid/Use Alternative

    relacorilant + irinotecan

    use alternative or D/C relacorilant >1wk prior to irinotecan start: combo may incr. irinotecan and active metabolite levels, risk of serious infection, myelosuppression, other toxicities (hepatic metabolism inhibited, additive effects)

  • ivacaftor
  • Lifyorli (relacorilant)
    +
    ivacaftor
    1 interaction

    Avoid/Use Alternative

    relacorilant + ivacaftor

    pts <6 mo: avoid combo; pts >6 mo decr. ivacaftor dose as follows: 6 mo-5 yo and 5-6.9 kg: give 25 mg 2x/wk; 6 mo-5 yo and 7-13.9 kg: give 50 mg 2x/wk; 6 mo-5 yo and >14 kg: give 75 mg 2x/wk; 6 yo and older: give 150 mg 2x/wk: combo may incr. ivacaftor levels, risk of adverse effects (hepatic metabolism inhibited)

  • ivosidenib
  • Lifyorli (relacorilant)
    +
    ivosidenib
    1 interaction

    Avoid/Use Alternative

    relacorilant + ivosidenib

    avoid combo: combo may incr. ivosidenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. relacorilant levels, efficacy (hepatic metabolism inhibited; hepatic metabolism possibly induced)

  • ixabepilone
  • Lifyorli (relacorilant)
    +
    ixabepilone
    1 interaction

    Avoid/Use Alternative

    relacorilant + ixabepilone

    use alternative or monitor CBC; consider decr. ixabepilone dose to 20 mg/m^2, wait 1wk after inhibitor D/C before incr. dose: combo may incr. ixabepilone levels, risk of serious infection, myelosuppression, other toxicity (hepatic metabolism inhibited, additive effects)

  • lapatinib
  • Lifyorli (relacorilant)
    +
    lapatinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + lapatinib

    use alternative or monitor ECG; consider decr. lapatinib dose to 500 mg/day: combo may incr. lapatinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • larotrectinib
  • Lifyorli (relacorilant)
    +
    larotrectinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + larotrectinib

    use alternative or decr. larotrectinib dose 50%: combo may incr. larotrectinib levels, risk of adverse effects (hepatic metabolism inhibited)

  • lefamulin
  • Lifyorli (relacorilant)
    +
    lefamulin
    1 interaction

    Avoid/Use Alternative

    relacorilant + lefamulin

    ORAL LEFAMULIN: avoid combo; IV lefamulin use OK: combo may incr. lefamulin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • lemborexant
  • Lifyorli (relacorilant)
    +
    lemborexant
    1 interaction

    Avoid/Use Alternative

    relacorilant + lemborexant

    avoid combo: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • lenacapavir
  • Lifyorli (relacorilant)
    +
    lenacapavir
    1 interaction

    Avoid/Use Alternative

    relacorilant + lenacapavir

    avoid combo if also combined with UGT1A1 and P-gp inhibitors; otherwise, caution advised: combo may incr. lenacapavir levels, risk of adverse effects (hepatic metabolism inhibited)

  • leniolisib
  • Lifyorli (relacorilant)
    +
    leniolisib
    1 interaction

    Avoid/Use Alternative

    relacorilant + leniolisib

    avoid combo: combo may incr. leniolisib levels, risk of adverse effects (hepatic metabolism inhibited)

  • levoketoconazole
  • Lifyorli (relacorilant)
    +
    levoketoconazole
    1 interaction

    Avoid/Use Alternative

    relacorilant + levoketoconazole

    avoid combo x2wk before and during levoketoconazole use: combo may incr. levoketoconazole levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • lorlatinib
  • Lifyorli (relacorilant)
    +
    lorlatinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + lorlatinib

    use alternative or monitor ECG and decr. lorlatinib dose as follows: if on lorlatinib 100 mg/day decr. to 75 mg/day, if on lorlatinib 75 mg/day decr. to 50 mg/day: combo may incr. lorlatinib levels, risk of PR prolongation, cardiac arrhythmias, AV block, other adverse effects; may decr. relacorilant levels, efficacy (hepatic metabolism inhibited; hepatic metabolism possibly induced)

  • lumacaftor/ivacaftor
  • Lifyorli (relacorilant)
    +
    lumacaftor/ ivacaftor
    1 interaction

    Avoid/Use Alternative

    relacorilant + lumacaftor/ ivacaftor

    avoid combo: combo may incr. ivacaftor levels, risk of adverse effects; may decr. relacorilant levels, efficacy (hepatic metabolism inhibited; hepatic metabolism possibly induced)

  • lurbinectedin
  • Lifyorli (relacorilant)
    +
    lurbinectedin
    1 interaction

    Avoid/Use Alternative

    relacorilant + lurbinectedin

    use alternative or monitor CBC; decr. lurbinectedin dose 50%: combo may incr. lurbinectedin levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • macitentan
  • Lifyorli (relacorilant)
    +
    macitentan
    1 interaction

    Avoid/Use Alternative

    relacorilant + macitentan

    avoid combo: combo may incr. macitentan levels, risk of adverse effects (hepatic metabolism inhibited)

  • mefloquine
  • Lifyorli (relacorilant)
    +
    mefloquine
    1 interaction

    Avoid/Use Alternative

    relacorilant + mefloquine

    avoid combo during and x15wk after stopping mefloquine tx: combo may incr. mefloquine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • meperidine
  • Lifyorli (relacorilant)
    +
    meperidine
    1 interaction

    Avoid/Use Alternative

    relacorilant + meperidine

    use alternative or monitor respiratory rate, ECG; consider decr. meperidine dose: combo may incr. meperidine levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • methadone
  • Lifyorli (relacorilant)
    +
    methadone
    1 interaction

    Avoid/Use Alternative

    relacorilant + methadone

    use alternative or monitor respiratory rate, ECG; consider decr. methadone dose: combo may incr. methadone levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • methylergonovine
  • Lifyorli (relacorilant)
    +
    methylergonovine
    1 interaction

    Avoid/Use Alternative

    relacorilant + methylergonovine

    avoid combo: combo may incr. methylergonovine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metabolism inhibited)

  • midazolam
  • Lifyorli (relacorilant)
    +
    midazolam
    1 interaction

    Avoid/Use Alternative

    relacorilant + midazolam

    avoid combo if midazolam nasal use; otherwise, monitor resp. rate, consider decr. midazolam dose: combo may incr. midazolam and active metabolite levels, risk of profound CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • midostaurin
  • Lifyorli (relacorilant)
    +
    midostaurin
    1 interaction

    Avoid/Use Alternative

    relacorilant + midostaurin

    consider alternative or monitor ECG, CBC: combo may incr. midostaurin levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • mifepristone
  • Lifyorli (relacorilant)
    +
    mifepristone
    1 interaction

    Avoid/Use Alternative

    relacorilant + mifepristone

    use alternative or decr. mifepristone dose as follows: if on mifepristone 1200 mg, decr. dose to 900 mg; if on mifepristone 900 mg, decr. dose to 600 mg, may titrate to max 900 mg/day; if on mifepristone 600 mg, decr. dose to 300 mg, may titrate to max 600 mg/day; if on mifepristone 300 mg, no dose adjustment needed; caution advised if pregnancy termination use: combo may incr. mifepristone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • mitapivat
  • Lifyorli (relacorilant)
    +
    mitapivat
    1 interaction

    Avoid/Use Alternative

    relacorilant + mitapivat

    avoid combo: combo may incr. mitapivat levels, risk of adverse effects; may decr. relacorilant levels, efficacy (hepatic metabolism inhibited; hepatic metabolism possibly induced)

  • mitotane
  • Lifyorli (relacorilant)
    +
    mitotane
    1 interaction

    Avoid/Use Alternative

    relacorilant + mitotane

    avoid combo: combo may decr. relacorilant levels, efficacy (hepatic metabolism possibly induced)

  • mobocertinib
  • Lifyorli (relacorilant)
    +
    mobocertinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + mobocertinib

    avoid combo: combo may incr. mobocertinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • natalizumab
  • Lifyorli (relacorilant)
    +
    natalizumab
    1 interaction

    Avoid/Use Alternative

    relacorilant + natalizumab

    avoid combo: combo may incr. risk of serious infection (additive effects)

  • neratinib
  • Lifyorli (relacorilant)
    +
    neratinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + neratinib

    avoid combo: combo may incr. neratinib levels, risk of adverse effects (hepatic metabolism inhibited)

  • nilotinib
  • Lifyorli (relacorilant)
    +
    nilotinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + nilotinib

    use alternative or monitor ECG, CBC; decr. nilotinib dose as follows: newly diagnosed CML: if on nilotinib 300 mg bid, decr. to 200 mg qd; if on nilotinib 142 mg bid, decr. to 95 mg qd; resistant or intolerant CML: if on nilotinib 400 mg bid, decr. to 300 mg qd; if on nilotinib 190 mg bid, decr. to 142 mg qd: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • nimodipine
  • Lifyorli (relacorilant)
    +
    nimodipine
    1 interaction

    Avoid/Use Alternative

    relacorilant + nimodipine

    use alternative or monitor BP: combo may incr. nimodipine levels, risk of hypotension, other adverse effects (hepatic metabolism inhibited)

  • nirogacestat
  • Lifyorli (relacorilant)
    +
    nirogacestat
    1 interaction

    Avoid/Use Alternative

    relacorilant + nirogacestat

    avoid combo: combo may incr. nirogacestat levels, risk of hypophosphatemia, other adverse effects (hepatic metabolism inhibited)

  • nisoldipine
  • Lifyorli (relacorilant)
    +
    nisoldipine
    1 interaction

    Avoid/Use Alternative

    relacorilant + nisoldipine

    use alternative or monitor BP: combo may incr. nisoldipine levels, risk of hypotension, other adverse effects (hepatic metabolism inhibited)

  • olaparib
  • Lifyorli (relacorilant)
    +
    olaparib
    1 interaction

    Avoid/Use Alternative

    relacorilant + olaparib

    use alternative or monitor CBC; decr. olaparib dose to 100 mg bid: combo may incr. olaparib levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • oliceridine
  • Lifyorli (relacorilant)
    +
    oliceridine
    1 interaction

    Avoid/Use Alternative

    relacorilant + oliceridine

    use alternative or monitor resp. rate, ECG; consider decr. oliceridine frequency: combo may incr. oliceridine levels, risk of CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • omaveloxolone
  • Lifyorli (relacorilant)
    +
    omaveloxolone
    1 interaction

    Avoid/Use Alternative

    relacorilant + omaveloxolone

    use alternative or decr. omaveloxolone dose to 50 mg/day: combo may incr. omaveloxolone levels, risk of adverse effects (hepatic metabolism inhibited)

  • orforglipron
  • Lifyorli (relacorilant)
    +
    orforglipron
    1 interaction

    Avoid/Use Alternative

    relacorilant + orforglipron

    avoid combo if also combined with OATP1B1 or OATP1B3 inhibitor; otherwise, adjust max orforglipron dose to 9 mg qd: combo may incr. orforglipron levels, risk of adverse effects (hepatic metabolism inhibited)

  • oxycodone
  • Lifyorli (relacorilant)
    +
    oxycodone
    1 interaction

    Avoid/Use Alternative

    relacorilant + oxycodone

    use alternative or monitor resp. rate; consider decr. oxycodone dose: combo may incr. oxycodone levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • palbociclib
  • Lifyorli (relacorilant)
    +
    palbociclib
    1 interaction

    Avoid/Use Alternative

    relacorilant + palbociclib

    use alternative or decr. palbociclib dose to 75 mg qd: combo may incr. palbociclib levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • palifermin
  • Lifyorli (relacorilant)
    +
    palifermin
    1 interaction

    Avoid/Use Alternative

    relacorilant + palifermin

    avoid palifermin admin. w/in 24h before, during tx, or w/in 24h after myelotoxic chemo; otherwise, caution advised: combo may incr. severity and duration of oral mucositis (antagonistic effects)

  • palovarotene
  • Lifyorli (relacorilant)
    +
    palovarotene
    1 interaction

    Avoid/Use Alternative

    relacorilant + palovarotene

    avoid combo: combo may incr. palovarotene levels, risk of adverse effects (hepatic metabolism inhibited)

  • pazopanib
  • Lifyorli (relacorilant)
    +
    pazopanib
    1 interaction

    Avoid/Use Alternative

    relacorilant + pazopanib

    use alternative or monitor ECG; decr. pazopanib dose to 400 mg qd: combo may incr. pazopanib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • pemigatinib
  • Lifyorli (relacorilant)
    +
    pemigatinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + pemigatinib

    use alternative or monitor phosphate and decr. pemigatinib dose as follows: if on pemigatinib 13.5 mg qd, decr. to 9 mg qd; if on pemigatinib 9 mg qd, decr. to 4.5 mg qd: combo may incr. pemigatinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metabolism inhibited)

  • penicillamine
  • Lifyorli (relacorilant)
    +
    penicillamine
    1 interaction

    Avoid/Use Alternative

    relacorilant + penicillamine

    use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • pentobarbital
  • Lifyorli (relacorilant)
    +
    pentobarbital
    1 interaction

    Avoid/Use Alternative

    relacorilant + pentobarbital

    avoid combo: combo may decr. relacorilant levels, efficacy (hepatic metabolism possibly induced)

  • pexidartinib
  • Lifyorli (relacorilant)
    +
    pexidartinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + pexidartinib

    use alternative or monitor LFTs, decr. pexidartinib dose as follows: if on pexidartinib 500 mg/day or 375 mg/day, decr. to 125 mg bid; if on pexidartinib 250 mg/day, decr. to 125 mg qd: combo may incr. pexidartinib levels, risk of hepatotoxicity, other adverse effects; may decr. relacorilant levels, efficacy (hepatic metabolism inhibited; hepatic metabolism possibly induced)

  • phenobarbital
  • Lifyorli (relacorilant)
    +
    phenobarbital
    1 interaction

    Avoid/Use Alternative

    relacorilant + phenobarbital

    avoid combo: combo may decr. relacorilant levels, efficacy (hepatic metabolism possibly induced)

  • phenytoin
  • Lifyorli (relacorilant)
    +
    phenytoin
    1 interaction

    Avoid/Use Alternative

    relacorilant + phenytoin

    avoid combo: combo may decr. relacorilant levels, efficacy (hepatic metabolism possibly induced)

  • pimecrolimus topical
  • Lifyorli (relacorilant)
    +
    pimecrolimus topical
    1 interaction

    Avoid/Use Alternative

    relacorilant + pimecrolimus topical

    avoid combo: combo may incr. pimecrolimus levels, risk of serious infection, other adverse effects (hepatic metabolism possibly inhibited, additive effects)

  • pirtobrutinib
  • Lifyorli (relacorilant)
    +
    pirtobrutinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + pirtobrutinib

    use alternative or monitor CBC and decr. pirtobrutinib dose by 50 mg; if on pirtobrutinib 50 mg qd, hold tx during relacorilant use: combo may incr. pirtobrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

  • ponatinib
  • Lifyorli (relacorilant)
    +
    ponatinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + ponatinib

    monitor CBC; if on ponatinib 45 mg/day, decr. to ponatinib 30 mg/day; if on ponatinib 30 mg/day, decr. to ponatinib 15 mg/day; if on ponatinib 15 mg/day, decr. to ponatinib 10 mg/day; if on ponatinib 10 mg/day, avoid relacorilant: combo may incr. ponatinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • pralsetinib
  • Lifyorli (relacorilant)
    +
    pralsetinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + pralsetinib

    use alternative or consider monitoring ECG, electrolytes and decr. pralsetinib dose as follows: if on pralsetinib 400 mg qd, decr. to 300 mg qd; if on pralsetinib 400 mg qd and also combined w/ a P-gp inhibitor: decr. to 200 mg qd; if on pralsetinib 300 mg qd, decr. to 200 mg qd; if on pralsetinib 200 mg qd, decr. to 100 mg qd: combo may incr. pralsetinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • primaquine
  • Lifyorli (relacorilant)
    +
    primaquine
    1 interaction

    Avoid/Use Alternative

    relacorilant + primaquine

    use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • primidone
  • Lifyorli (relacorilant)
    +
    primidone
    1 interaction

    Avoid/Use Alternative

    relacorilant + primidone

    avoid combo: combo may decr. relacorilant levels, efficacy (hepatic metabolism possibly induced)

  • propafenone
  • Lifyorli (relacorilant)
    +
    propafenone
    1 interaction

    Avoid/Use Alternative

    relacorilant + propafenone

    if CYP2D6 poor metabolizer or if also combined with CYP2D6 inhibitor, avoid combo; otherwise, monitor ECG, BP: combo may incr. propafenone levels, risk of QT prolongation, cardiac arrhythmias, hypotension, other adverse effects (hepatic metabolism inhibited)

  • quizartinib
  • Lifyorli (relacorilant)
    +
    quizartinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + quizartinib

    monitor ECG, electrolytes, and adjust quizartinib dose as follows: if on quizartinib 53 mg qd, decr. to 26.5 mg qd; if on quizartinib 35.4 mg qd, decr. to 17.7 mg qd; if on quizartinib 26.5 mg qd, decr. to 17.7 mg qd; avoid combo if on quizartinib 17.7 mg qd: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • rabies vaccine
  • Lifyorli (relacorilant)
    +
    rabies vaccine
    1 interaction

    Avoid/Use Alternative

    relacorilant + rabies vaccine

    if possible, avoid immunosuppressive tx or vaccinate at least 2wk before relacorilant start; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

  • radium Ra 223 dichloride
  • Lifyorli (relacorilant)
    +
    radium Ra 223 dichloride
    1 interaction

    Avoid/Use Alternative

    relacorilant + radium Ra 223 dichloride

    use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • red yeast rice
  • Lifyorli (relacorilant)
    +
    red yeast rice
    1 interaction

    Avoid/Use Alternative

    relacorilant + red yeast rice

    use alternative or monitor CK, myopathy symptoms with large amounts of red yeast rice: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited, red yeast rice contains varying amounts of lovastatin)

  • regorafenib
  • Lifyorli (relacorilant)
    +
    regorafenib
    1 interaction

    Avoid/Use Alternative

    relacorilant + regorafenib

    avoid combo: combo may incr. regorafenib levels, risk of serious infection, other adverse effects (hepatic metabolism inhibited, additive effects)

  • remibrutinib
  • Lifyorli (relacorilant)
    +
    remibrutinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + remibrutinib

    avoid combo: combo may incr. remibrutinib levels, risk of adverse effects (hepatic metabolism inhibited)

  • repotrectinib
  • Lifyorli (relacorilant)
    +
    repotrectinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + repotrectinib

    avoid combo; D/C relacorilant 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects; may decr. relacorilant levels, efficacy (hepatic metabolism inhibited; hepatic metabolism possibly induced)

  • retapamulin topical
  • Lifyorli (relacorilant)
    +
    retapamulin topical
    1 interaction

    Avoid/Use Alternative

    relacorilant + retapamulin topical

    avoid combo in pts <24 mo; otherwise, caution advised: combo may incr. retapamulin levels, risk of adverse effects (hepatic metabolism inhibited)

  • ribociclib
  • Lifyorli (relacorilant)
    +
    ribociclib
    1 interaction

    Avoid/Use Alternative

    relacorilant + ribociclib

    use alternative or monitor ECG, electrolytes, CBC; decr. ribociclib dose as follows: EARLY BREAST CA: decr. ribociclib dose to 200 mg qd; ADVANCED OR METASTATIC BREAST CA: decr. ribociclib dose to 400 mg qd: combo may incr. ribociclib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • rifabutin
  • Lifyorli (relacorilant)
    +
    rifabutin
    1 interaction

    Avoid/Use Alternative

    relacorilant + rifabutin

    avoid combo: combo may incr. rifabutin levels, risk of myelosuppression, uveitis, other adverse effects; may decr. relacorilant levels, efficacy; may incr. risk of myelosuppression (hepatic metabolism inhibited; hepatic metabolism possibly induced; additive effects)

  • rifampin
  • Lifyorli (relacorilant)
    +
    rifampin
    1 interaction

    Avoid/Use Alternative

    relacorilant + rifampin

    avoid combo: combo may decr. relacorilant levels, efficacy (hepatic metabolism possibly induced)

  • rilzabrutinib
  • Lifyorli (relacorilant)
    +
    rilzabrutinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + rilzabrutinib

    avoid combo if relacorilant use greater than 7 days; use alternative or hold rilzabrutinib if relacorilant use less than 7 days: combo may incr. rilzabrutinib levels, risk of serious infection, other adverse effects (hepatic metabolism inhibited, additive effects)

  • rimegepant
  • Lifyorli (relacorilant)
    +
    rimegepant
    1 interaction

    Avoid/Use Alternative

    relacorilant + rimegepant

    avoid combo: combo may incr. rimegepant levels, risk of adverse effects (hepatic metabolism inhibited)

  • rivaroxaban
  • Lifyorli (relacorilant)
    +
    rivaroxaban
    1 interaction

    Avoid/Use Alternative

    relacorilant + rivaroxaban

    avoid combo if also combined w/ P-gp inhibitor; otherwise, monitor bleeding signs/symptoms: combo may incr. rivaroxaban levels, risk of bleeding, other adverse effects (hepatic metabolism inhibited)

  • ropeginterferon alfa-2b
  • Lifyorli (relacorilant)
    +
    ropeginterferon alfa-2b
    1 interaction

    Avoid/Use Alternative

    relacorilant + ropeginterferon alfa-2b

    use alternative or monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

  • ruxolitinib
  • Lifyorli (relacorilant)
    +
    ruxolitinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + ruxolitinib

    monitor CBC; ACUTE OR CHRONIC GVHD: no adjustment; MYELOFIBROSIS INITIATION: decr. ruxolitinib start dose to 10 mg bid if Plt >100,000 or 5 mg qd if Plt 50,000-100,000; POLYCYTHEMIA VERA INITIATION: decr. ruxolitinib start dose to 5 mg bid; MYELOFIBROSIS AND POLYCYTHEMIA VERA ONGOING TX: decr. ruxolitinib maintenance dose by 50%; avoid combo if maintenance dose is 5 mg/day: combo may incr. ruxolitinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

  • ruxolitinib topical
  • Lifyorli (relacorilant)
    +
    ruxolitinib topical
    1 interaction

    Avoid/Use Alternative

    relacorilant + ruxolitinib topical

    avoid combo: combo may incr. ruxolitinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

  • salmeterol inhaled
  • Lifyorli (relacorilant)
    +
    salmeterol inhaled
    1 interaction

    Avoid/Use Alternative

    relacorilant + salmeterol inhaled

    avoid combo: combo may incr. salmeterol exposure, risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other adverse effects (hepatic metabolism inhibited)

  • sebetralstat
  • Lifyorli (relacorilant)
    +
    sebetralstat
    1 interaction

    Avoid/Use Alternative

    relacorilant + sebetralstat

    avoid combo: combo may incr. sebetralstat levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • selpercatinib
  • Lifyorli (relacorilant)
    +
    selpercatinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + selpercatinib

    use alternative or monitor ECG, electrolytes; decr. selpercatinib dose as follows: if on selpercatinib 40 mg tid, decr. to 40 mg qd; if on selpercatinib 80 mg bid, decr. to 40 mg bid; if on selpercatinib 120 mg bid, decr. to 40 mg bid; if on selpercatinib 160 mg bid, decr. to 80 mg bid: combo may incr. selpercatinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • selumetinib
  • Lifyorli (relacorilant)
    +
    selumetinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + selumetinib

    use alternative or monitor LVEF, CK, myopathy symptoms; decr. selumetinib dose as follows: if on selumetinib 25 mg/m^2 bid, decr. to 20 mg/m^2 bid; if on selumetinib 20 mg/m^2 bid, decr. to 15 mg/m^2 bid; see selumetinib pkg insert for specific dose adjustments: combo may incr. selumetinib levels, risk of cardiotoxicity, myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited)

  • sevabertinib
  • Lifyorli (relacorilant)
    +
    sevabertinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + sevabertinib

    use alternative or decr. sevabertinib dose as follows: if on sevabertinib 20 mg bid, decr. to 10 mg bid; if on sevabertinib 10 mg bid, decr. to 10 mg qd; if on sevabertinib 10 mg qd, hold sevabertinib until relacorilant D/C: combo may incr. sevabertinib levels, risk of adverse effects (hepatic metabolism inhibited)

  • sildenafil
  • Lifyorli (relacorilant)
    +
    sildenafil
    1 interaction

    Avoid/Use Alternative

    relacorilant + sildenafil

    PULMONARY HTN: avoid combo; ERECTILE DYSFUNCTION: monitor BP; consider decr. sildenafil start dose to 25 mg: combo may incr. sildenafil levels, risk of hypotension (including syncope), priapism, other adverse effects (hepatic metabolism inhibited)

  • siponimod
  • Lifyorli (relacorilant)
    +
    siponimod
    1 interaction

    Avoid/Use Alternative

    relacorilant + siponimod

    if also combined with strong CYP2C9 inhibitor, avoid combo; if also combined with moderate CYP2C9 inhibitor, monitor HR, ECG: combo may incr. siponimod levels, risk of PR interval prolongation, AV block, bradycardia, serious infection, other adverse effects; infection risk may be prolonged during and x3-4wk after siponimod use (hepatic metabolism inhibited, additive effects)

  • sipuleucel-T
  • Lifyorli (relacorilant)
    +
    sipuleucel-T
    1 interaction

    Avoid/Use Alternative

    relacorilant + sipuleucel-T

    consider alternative or decr. relacorilant dose or D/C during leukapheresis and sipuleucel-T: combo may decr. sipuleucel-T efficacy; may incr. risk of adverse effects (immunosuppressive effects)

  • sirolimus
  • Lifyorli (relacorilant)
    +
    sirolimus
    1 interaction

    Avoid/Use Alternative

    relacorilant + sirolimus

    use alternative or monitor sirolimus levels, CBC: combo may incr. sirolimus levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

  • sirolimus albumin-bound
  • Lifyorli (relacorilant)
    +
    sirolimus albumin-bound
    1 interaction

    Avoid/Use Alternative

    relacorilant + sirolimus albumin-bound

    avoid combo: combo may incr. sirolimus albumin-bound levels, risk of serious infection, myelosuppression, bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited, additive effects)

  • sonidegib
  • Lifyorli (relacorilant)
    +
    sonidegib
    1 interaction

    Avoid/Use Alternative

    relacorilant + sonidegib

    avoid combo: combo may incr. sonidegib levels, risk of adverse effects (hepatic metabolism inhibited)

  • sparsentan
  • Lifyorli (relacorilant)
    +
    sparsentan
    1 interaction

    Avoid/Use Alternative

    relacorilant + sparsentan

    avoid combo or hold sparsentan during relacorilant use: combo may incr. sparsentan levels, risk of hypotension (incl. orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • St. John's wort
  • Lifyorli (relacorilant)
    +
    St. John's wort
    1 interaction

    Avoid/Use Alternative

    relacorilant + St. John's wort

    avoid combo: combo may decr. relacorilant levels, efficacy (hepatic metabolism possibly induced)

  • sufentanil
  • Lifyorli (relacorilant)
    +
    sufentanil
    1 interaction

    Avoid/Use Alternative

    relacorilant + sufentanil

    use alternative or monitor resp. rate, consider decr. sufentanil dose or frequency: combo may incr. sufentanil levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • sunitinib
  • Lifyorli (relacorilant)
    +
    sunitinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + sunitinib

    use alternative or monitor ECG, electrolytes; consider decr. sunitinib to minimum dose as follows: GIST or RCC: 37.5 mg/day, 4wk on, 2wk off; PNET: 25 mg/day: combo may incr. sunitinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • sunvozertinib
  • Lifyorli (relacorilant)
    +
    sunvozertinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + sunvozertinib

    use alternative or decr. sunvozertinib dose to 150 mg once daily: combo may incr. sunvozertinib levels, risk of adverse effects (hepatic metabolism inhibited)

  • suvorexant
  • Lifyorli (relacorilant)
    +
    suvorexant
    1 interaction

    Avoid/Use Alternative

    relacorilant + suvorexant

    avoid combo: combo may incr. suvorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • tadalafil
  • Lifyorli (relacorilant)
    +
    tadalafil
    1 interaction

    Avoid/Use Alternative

    relacorilant + tadalafil

    PULMONARY HTN and BENIGN PROSTATIC HYPERPLASIA: avoid combo; ERECTILE DYSFUNCTION: monitor BP; adjust tadalafil max dose to 10 mg/dose q72h if prn dosing regimen, 2.5 mg/day if daily dosing regimen: combo may incr. tadalafil levels, risk of hypotension, priapism, other adverse effects (hepatic metabolism inhibited)

  • taletrectinib
  • Lifyorli (relacorilant)
    +
    taletrectinib
    1 interaction

    Avoid/Use Alternative

    relacorilant + taletrectinib

    avoid combo: combo may incr. taletrectinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • tamsulosin
  • Lifyorli (relacorilant)
    +
    tamsulosin
    1 interaction

    Avoid/Use Alternative

    relacorilant + tamsulosin

    avoid combo: combo may incr. tamsulosin levels, risk of hypotension (incl. orthostasis, syncope), other adverse effects (hepatic metabolism inhibited)

  • tazemetostat
  • Lifyorli (relacorilant)
    +
    tazemetostat
    1 interaction

    Avoid/Use Alternative

    relacorilant + tazemetostat

    use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • temsirolimus
  • Lifyorli (relacorilant)
    +
    temsirolimus
    1 interaction

    Avoid/Use Alternative

    relacorilant + temsirolimus

    use alternative or monitor CBC; consider decr. temsirolimus dose to 12.5 mg/wk: combo may incr. temsirolimus and active metabolite sirolimus levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

  • thiotepa
  • Lifyorli (relacorilant)
    +
    thiotepa
    1 interaction

    Avoid/Use Alternative

    relacorilant + thiotepa

    use alternative or monitor CBC: combo may incr. thiotepa levels, risk of serious infection, myelosuppression, other adverse effects; may decr. thiotepa active metabolite levels, efficacy (hepatic metabolism inhibited, decr. metabolite formation, additive effects)

  • ticagrelor
  • Lifyorli (relacorilant)
    +
    ticagrelor
    1 interaction

    Avoid/Use Alternative

    relacorilant + ticagrelor

    avoid combo: combo may incr. ticagrelor levels, risk of dyspnea, bleeding, other adverse effects (hepatic metabolism inhibited)

  • toremifene
  • Lifyorli (relacorilant)
    +
    toremifene
    1 interaction

    Avoid/Use Alternative

    relacorilant + toremifene

    use alternative or monitor ECG: combo may incr. toremifene levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • trabectedin
  • Lifyorli (relacorilant)
    +
    trabectedin
    1 interaction

    Avoid/Use Alternative

    relacorilant + trabectedin

    use alternative or if relacorilant short-term use, administer relacorilant 1wk after trabectedin infusion; D/C relacorilant on day prior to next trabectedin infusion: combo may incr. trabectedin levels, risk of serious infection, myelosuppression, cardiotoxicity, hepatotoxicity, other adverse effects (hepatic metabolism inhibited, additive effects)

  • tramadol
  • Lifyorli (relacorilant)
    +
    tramadol
    1 interaction

    Avoid/Use Alternative

    relacorilant + tramadol

    use alternative or monitor resp. rate, ECG, consider decr. tramadol dose: combo may incr. tramadol and active metabolite levels, risk of CNS and resp. depression, psychomotor impairment, seizures, serotonin syndrome, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, may incr. production of active metabolite)

  • trazodone
  • Lifyorli (relacorilant)
    +
    trazodone
    1 interaction

    Avoid/Use Alternative

    relacorilant + trazodone

    use alternative or monitor ECG, BP; consider decr. trazodone dose: combo may incr. trazodone levels, risk of QT prolongation, cardiac arrhythmias, hypotension (incl. orthostasis, syncope), other adverse effects (hepatic metabolism inhibited)

  • tretinoin
  • Lifyorli (relacorilant)
    +
    tretinoin
    1 interaction

    Avoid/Use Alternative

    relacorilant + tretinoin

    use alternative: combo may incr. tretinoin levels, risk of adverse effects (hepatic metabolism inhibited)

  • valganciclovir
  • Lifyorli (relacorilant)
    +
    valganciclovir
    1 interaction

    Avoid/Use Alternative

    relacorilant + valganciclovir

    use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • vamorolone
  • Lifyorli (relacorilant)
    +
    vamorolone
    1 interaction

    Avoid/Use Alternative

    relacorilant + vamorolone

    use alternative: combo may incr. vamorolone levels, risk of systemic corticosteroid effects incl. Cushing syndrome and adrenal suppression, serious infection, other adverse effects; may decr. efficacy of both drugs (hepatic metabolism inhibited, additive effects; antagonistic effects)

  • vardenafil
  • Lifyorli (relacorilant)
    +
    vardenafil
    1 interaction

    Avoid/Use Alternative

    relacorilant + vardenafil

    max vardenafil dose 2.5 mg/24h; avoid combo w/ ODT form: combo may incr. vardenafil levels, risk of QT prolongation, cardiac arrhythmias, hypotension, priapism, other adverse effects (hepatic metabolism inhibited)

  • vemurafenib
  • Lifyorli (relacorilant)
    +
    vemurafenib
    1 interaction

    Avoid/Use Alternative

    relacorilant + vemurafenib

    use alternative or monitor ECG; consider decr. vemurafenib dose: combo may incr. vemurafenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • vinblastine
  • Lifyorli (relacorilant)
    +
    vinblastine
    1 interaction

    Avoid/Use Alternative

    relacorilant + vinblastine

    use alternative or monitor CBC: combo may incr. vinblastine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metabolism inhibited, additive effects)

  • vincristine
  • Lifyorli (relacorilant)
    +
    vincristine
    1 interaction

    Avoid/Use Alternative

    relacorilant + vincristine

    avoid combo: combo may incr. vincristine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metabolism inhibited, additive effects)

  • vinorelbine
  • Lifyorli (relacorilant)
    +
    vinorelbine
    1 interaction

    Avoid/Use Alternative

    relacorilant + vinorelbine

    use alternative or monitor CBC: combo may incr. vinorelbine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metabolism inhibited, additive effects)

  • vorapaxar
  • Lifyorli (relacorilant)
    +
    vorapaxar
    1 interaction

    Avoid/Use Alternative

    relacorilant + vorapaxar

    avoid combo: combo may incr. vorapaxar levels, risk of adverse effects (hepatic metabolism inhibited)

Monitor/Modify Tx

  • abemaciclib
  • Lifyorli (relacorilant)
    +
    abemaciclib
    1 interaction

    Monitor/Modify Tx

    relacorilant + abemaciclib

    decr. abemaciclib 150-200 mg bid dose to 100 mg bid; decr. abemaciclib 100 mg bid dose to 50 mg bid: combo may incr. abemaciclib levels, risk of adverse effects (hepatic metabolism inhibited)

  • aficamten
  • Lifyorli (relacorilant)
    +
    aficamten
    1 interaction

    Monitor/Modify Tx

    relacorilant + aficamten

    monitor cardiac fxn, incl. LVEF: combo may incr. aficamten levels, risk of cardiotoxicity, other adverse effects (hepatic metabolism inhibited)

  • albendazole
  • Lifyorli (relacorilant)
    +
    albendazole
    1 interaction

    Monitor/Modify Tx

    relacorilant + albendazole

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • alemtuzumab
  • Lifyorli (relacorilant)
    +
    alemtuzumab
    1 interaction

    Monitor/Modify Tx

    relacorilant + alemtuzumab

    monitor CBC; myelosuppression risk may be lower with alemtuzumab doses used for MS: combo may incr. risk of serious infection, myelosuppression (additive effects)

  • allopurinol
  • Lifyorli (relacorilant)
    +
    allopurinol
    1 interaction

    Monitor/Modify Tx

    relacorilant + allopurinol

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • aminophylline
  • Lifyorli (relacorilant)
    +
    aminophylline
    1 interaction

    Monitor/Modify Tx

    relacorilant + aminophylline

    monitor theophylline levels: combo may incr. theophylline levels, risk of cardiac arrhythmias, seizures, other toxicities (hepatic metabolism inhibited, aminophylline converted to theophylline)

  • amlodipine
  • Lifyorli (relacorilant)
    +
    amlodipine
    1 interaction

    Monitor/Modify Tx

    relacorilant + amlodipine

    monitor BP: combo may incr. (lev)amlodipine levels, risk of hypotension, edema, other adverse effects (hepatic metabolism inhibited)

  • anthrax vaccine
  • Lifyorli (relacorilant)
    +
    anthrax vaccine
    1 interaction

    Monitor/Modify Tx

    relacorilant + anthrax vaccine

    if possible, vaccinate at least 2wk before relacorilant start; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

  • anti-thymocyte globulin
  • Lifyorli (relacorilant)
    +
    anti-thymocyte globulin
    1 interaction

    Monitor/Modify Tx

    relacorilant + anti-thymocyte globulin

    monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

  • aripiprazole oral
  • Lifyorli (relacorilant)
    +
    aripiprazole oral
    1 interaction

    Monitor/Modify Tx

    relacorilant + aripiprazole oral

    decr. PO aripiprazole dose 50%; if also CYP2D6 PM or also combined w/ strong CYP2D6 inhibitor, decr. PO aripiprazole dose 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

  • artemether/lumefantrine
  • Lifyorli (relacorilant)
    +
    artemether/ lumefantrine
    1 interaction

    Monitor/Modify Tx

    relacorilant + artemether/ lumefantrine

    monitor ECG: combo may incr. artemether/lumefantrine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • asciminib
  • Lifyorli (relacorilant)
    +
    asciminib
    1 interaction

    Monitor/Modify Tx

    relacorilant + asciminib

    if asciminib 200 mg bid, monitor CBC; otherwise, caution advised: combo may incr. asciminib levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • atazanavir
  • Lifyorli (relacorilant)
    +
    atazanavir
    1 interaction

    Monitor/Modify Tx

    relacorilant + atazanavir

    monitor bilirubin: combo may incr. atazanavir levels, risk of hyperbilirubinemia, other adverse effects (hepatic metabolism inhibited)

  • atidarsagene autotemcel
  • Lifyorli (relacorilant)
    +
    atidarsagene autotemcel
    1 interaction

    Monitor/Modify Tx

    relacorilant + atidarsagene autotemcel

    monitor CBC, bleeding signs/symptoms: combo may incr. risk of serious infection, myelosuppression (additive effects)

  • atogepant
  • Lifyorli (relacorilant)
    +
    atogepant
    1 interaction

    Monitor/Modify Tx

    relacorilant + atogepant

    decr. atogepant dose to 10 mg/day: combo may incr. atogepant levels, risk of adverse effects (hepatic metabolism inhibited)

  • atorvastatin
  • Lifyorli (relacorilant)
    +
    atorvastatin
    1 interaction

    Monitor/Modify Tx

    relacorilant + atorvastatin

    monitor CK, myopathy sx: combo may incr. atorvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited)

  • auranofin
  • Lifyorli (relacorilant)
    +
    auranofin
    1 interaction

    Monitor/Modify Tx

    relacorilant + auranofin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • avacopan
  • Lifyorli (relacorilant)
    +
    avacopan
    1 interaction

    Monitor/Modify Tx

    relacorilant + avacopan

    decr. avacopan dose to 30 mg qd: combo may incr. avacopan levels, risk of serious infection, other adverse effects (hepatic metabolism inhibited, additive effects)

  • avatrombopag
  • Lifyorli (relacorilant)
    +
    avatrombopag
    1 interaction

    Monitor/Modify Tx

    relacorilant + avatrombopag

    CHRONIC IMMUNE THROMBOCYTOPENIA: monitor platelets, thrombosis s/sx; if avatrombopag tablet also combined w/ a moderate or strong CYP2C9 inhibitor, decr. start dose to 20 mg 3x/wk; if avatrombopag sprinkle also combined w/ a moderate or strong CYP2C9 inhibitor, decr. start dose to 10 mg 3x/wk; CHRONIC LIVER DZ: monitor platelets, thrombosis s/sx: combo may incr. avatrombopag levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited)

  • azathioprine
  • Lifyorli (relacorilant)
    +
    azathioprine
    1 interaction

    Monitor/Modify Tx

    relacorilant + azathioprine

    monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

  • balsalazide
  • Lifyorli (relacorilant)
    +
    balsalazide
    1 interaction

    Monitor/Modify Tx

    relacorilant + balsalazide

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • baricitinib
  • Lifyorli (relacorilant)
    +
    baricitinib
    1 interaction

    Monitor/Modify Tx

    relacorilant + baricitinib

    monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

  • bedaquiline
  • Lifyorli (relacorilant)
    +
    bedaquiline
    1 interaction

    Monitor/Modify Tx

    relacorilant + bedaquiline

    monitor ECG: combo may incr. bedaquiline levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • benznidazole
  • Lifyorli (relacorilant)
    +
    benznidazole
    1 interaction

    Monitor/Modify Tx

    relacorilant + benznidazole

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • betibeglogene autotemcel
  • Lifyorli (relacorilant)
    +
    betibeglogene autotemcel
    1 interaction

    Monitor/Modify Tx

    relacorilant + betibeglogene autotemcel

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

  • bortezomib
  • Lifyorli (relacorilant)
    +
    bortezomib
    1 interaction

    Monitor/Modify Tx

    relacorilant + bortezomib

    monitor CBC; consider decr. bortezomib dose: combo may incr. bortezomib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

  • brentuximab vedotin
  • Lifyorli (relacorilant)
    +
    brentuximab vedotin
    1 interaction

    Monitor/Modify Tx

    relacorilant + brentuximab vedotin

    monitor CBC, LFTs: combo may incr. brentuximab vedotin levels, risk of serious infection, myelosuppression, peripheral neuropathy, hepatotoxicity, other adverse effects (hepatic metabolism inhibited, additive effects)

  • brexpiprazole
  • Lifyorli (relacorilant)
    +
    brexpiprazole
    1 interaction

    Monitor/Modify Tx

    relacorilant + brexpiprazole

    decr. brexpiprazole dose 50%; if CYP2D6 poor metabolizer or if also combined w/ moderate or strong CYP2D6 inhibitor, decr. brexpiprazole dose 75%: combo may incr. brexpiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

  • butorphanol
  • Lifyorli (relacorilant)
    +
    butorphanol
    1 interaction

    Monitor/Modify Tx

    relacorilant + butorphanol

    monitor respiratory rate; consider decr. butorphanol dose: combo may incr. butorphanol levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • chikungunya vaccine
  • Lifyorli (relacorilant)
    +
    chikungunya vaccine
    1 interaction

    Monitor/Modify Tx

    relacorilant + chikungunya vaccine

    if possible, vaccinate at least 2wk before relacorilant start; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

  • cidofovir
  • Lifyorli (relacorilant)
    +
    cidofovir
    1 interaction

    Monitor/Modify Tx

    relacorilant + cidofovir

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • cilostazol
  • Lifyorli (relacorilant)
    +
    cilostazol
    1 interaction

    Monitor/Modify Tx

    relacorilant + cilostazol

    decr. cilostazol dose to 50 mg bid: combo may incr. cilostazol levels, risk of adverse effects (hepatic metabolism inhibited)

  • cinacalcet
  • Lifyorli (relacorilant)
    +
    cinacalcet
    1 interaction

    Monitor/Modify Tx

    relacorilant + cinacalcet

    monitor iPTH, calcium, ECG: combo may incr. cinacalcet levels, risk of severe hypocalcemia (incl. life-threatening), QT prolongation, cardiac arrhythmias, seizures, other adverse effects (hepatic metabolism inhibited)

  • clarithromycin
  • Lifyorli (relacorilant)
    +
    clarithromycin
    1 interaction

    Monitor/Modify Tx

    relacorilant + clarithromycin

    monitor ECG: combo may incr. clarithromycin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • clonazepam
  • Lifyorli (relacorilant)
    +
    clonazepam
    1 interaction

    Monitor/Modify Tx

    relacorilant + clonazepam

    monitor resp. rate: combo may incr. clonazepam levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • clorazepate
  • Lifyorli (relacorilant)
    +
    clorazepate
    1 interaction

    Monitor/Modify Tx

    relacorilant + clorazepate

    monitor resp. rate: combo may incr. clorazepate levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • clozapine
  • Lifyorli (relacorilant)
    +
    clozapine
    1 interaction

    Monitor/Modify Tx

    relacorilant + clozapine

    monitor ECG, BP, HR, CBC; consider decr. clozapine dose: combo may incr. clozapine levels, risk of QT prolongation, cardiac arrhythmias, hypotension, bradycardia, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

  • copper histidinate
  • Lifyorli (relacorilant)
    +
    copper histidinate
    1 interaction

    Monitor/Modify Tx

    relacorilant + copper histidinate

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • COVID-19 vaccine
  • Lifyorli (relacorilant)
    +
    COVID-19 vaccine
    1 interaction

    Monitor/Modify Tx

    relacorilant + COVID-19 vaccine

    if possible, vaccinate at least 2wk before or 3mo after relacorilant use; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

  • cyclophosphamide
  • Lifyorli (relacorilant)
    +
    cyclophosphamide
    1 interaction

    Monitor/Modify Tx

    relacorilant + cyclophosphamide

    monitor CBC: combo may decr. cyclophosphamide active metabolite levels, efficacy; may incr. risk of serious infection, myelosuppression (hepatic metabolism possibly inhibited, decr. conversion to active metabolite; additive effects)

  • cyclosporine
  • Lifyorli (relacorilant)
    +
    cyclosporine
    1 interaction

    Monitor/Modify Tx

    relacorilant + cyclosporine

    monitor cyclosporine levels, renal fxn: combo may incr. cyclosporine levels, risk of serious infection, nephrotoxicity, other adverse effects (hepatic metabolism inhibited, additive effects)

  • dapsone
  • Lifyorli (relacorilant)
    +
    dapsone
    1 interaction

    Monitor/Modify Tx

    relacorilant + dapsone

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • darifenacin
  • Lifyorli (relacorilant)
    +
    darifenacin
    1 interaction

    Monitor/Modify Tx

    relacorilant + darifenacin

    adjust max darifenacin dose to 7.5 mg/day: combo may incr. darifenacin levels, risk of adverse effects (hepatic metabolism inhibited)

  • deferasirox
  • Lifyorli (relacorilant)
    +
    deferasirox
    1 interaction

    Monitor/Modify Tx

    relacorilant + deferasirox

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • deuruxolitinib
  • Lifyorli (relacorilant)
    +
    deuruxolitinib
    1 interaction

    Monitor/Modify Tx

    relacorilant + deuruxolitinib

    monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

  • diazepam
  • Lifyorli (relacorilant)
    +
    diazepam
    1 interaction

    Monitor/Modify Tx

    relacorilant + diazepam

    monitor respiratory rate: combo may incr. diazepam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • diazoxide
  • Lifyorli (relacorilant)
    +
    diazoxide
    1 interaction

    Monitor/Modify Tx

    relacorilant + diazoxide

    monitor glucose: combo may incr. diazoxide levels, risk of hyperglycemia, other adverse effects (hepatic metabolism inhibited)

  • diltiazem
  • Lifyorli (relacorilant)
    +
    diltiazem
    1 interaction

    Monitor/Modify Tx

    relacorilant + diltiazem

    monitor BP, HR: combo may incr. diltiazem levels, risk of hypotension, bradycardia, AV block, other adverse effects (hepatic metabolism inhibited)

  • diphtheria/tetanus vaccine
  • Lifyorli (relacorilant)
    +
    diphtheria/ tetanus vaccine
    1 interaction

    Monitor/Modify Tx

    relacorilant + diphtheria/ tetanus vaccine

    if possible, vaccinate at least 2wk before relacorilant start; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

  • diphtheria/tetanus/pertussis vaccine
  • Lifyorli (relacorilant)
    +
    diphtheria/ tetanus/ pertussis vaccine
    1 interaction

    Monitor/Modify Tx

    relacorilant + diphtheria/ tetanus/ pertussis vaccine

    if possible, vaccinate at least 2wk before relacorilant start; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

  • dofetilide
  • Lifyorli (relacorilant)
    +
    dofetilide
    1 interaction

    Monitor/Modify Tx

    relacorilant + dofetilide

    monitor ECG: combo may incr. dofetilide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • doxercalciferol
  • Lifyorli (relacorilant)
    +
    doxercalciferol
    1 interaction

    Monitor/Modify Tx

    relacorilant + doxercalciferol

    monitor efficacy: combo may decr. doxercalciferol efficacy (hepatic metabolism inhibited, decreased conversion to activated vitamin D)

  • drospirenone (contraceptive)
  • Lifyorli (relacorilant)
    +
    drospirenone (contraceptive)
    1 interaction

    Monitor/Modify Tx

    relacorilant + drospirenone (contraceptive)

    monitor potassium: combo may incr. drospirenone levels, risk of hyperkalemia, other adverse effects (hepatic metabolism inhibited)

  • drospirenone (hormone replacement)
  • Lifyorli (relacorilant)
    +
    drospirenone (hormone replacement)
    1 interaction

    Monitor/Modify Tx

    relacorilant + drospirenone (hormone replacement)

    monitor potassium: combo may incr. drospirenone levels, risk of hyperkalemia, other adverse effects (hepatic metabolism inhibited)

  • ebola vaccine, live
  • Lifyorli (relacorilant)
    +
    ebola vaccine, live
    1 interaction

    Monitor/Modify Tx

    relacorilant + ebola vaccine, live

    consider vaccinating at least 4wk before or 3mo after relacorilant use: combo may result in inadequate vaccine response; may incr. risk of mild vesicular stomatitis virus infection (immunosuppressive effects, recombinant vaccine with vesicular stomatitis virus vector)

  • efavirenz
  • Lifyorli (relacorilant)
    +
    efavirenz
    1 interaction

    Monitor/Modify Tx

    relacorilant + efavirenz

    monitor ECG: combo may incr. efavirenz levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. relacorilant levels, efficacy (hepatic metabolism inhibited; hepatic metabolism possibly induced)

  • efbemalenograstim alfa
  • Lifyorli (relacorilant)
    +
    efbemalenograstim alfa
    1 interaction

    Monitor/Modify Tx

    relacorilant + efbemalenograstim alfa

    give efbemalenograstim at least 24h after or at least 14 days before myelosuppressive chemo: combo may decr. efbemalenograstim efficacy (antagonistic effects)

  • eflapegrastim (G-CSF)
  • Lifyorli (relacorilant)
    +
    eflapegrastim (G-CSF)
    1 interaction

    Monitor/Modify Tx

    relacorilant + eflapegrastim (G-CSF)

    give eflapegrastim at least 24h after or at least 14 days before myelosuppressive chemo: combo may decr. eflapegrastim efficacy (antagonistic effects)

  • elexacaftor/tezacaftor/ivacaftor
  • Lifyorli (relacorilant)
    +
    elexacaftor/ tezacaftor/ ivacaftor
    1 interaction

    Monitor/Modify Tx

    relacorilant + elexacaftor/ tezacaftor/ ivacaftor

    2-5 YO: decr. usual elexacaftor/tezacaftor/ivacaftor morning dose to one packet 2x/wk (3-4 days apart), no ivacaftor evening doses; 6 YO AND OLDER: decr. usual elexacaftor/tezacaftor/ivacaftor morning dose to two tablets 2x/wk (3-4 days apart), no ivacaftor evening doses: combo may incr. elexacaftor/tezacaftor/ivacaftor levels, risk of adverse effects (hepatic metabolism inhibited)

  • elivaldogene autotemcel
  • Lifyorli (relacorilant)
    +
    elivaldogene autotemcel
    1 interaction

    Monitor/Modify Tx

    relacorilant + elivaldogene autotemcel

    monitor CBC, bleeding s/sx: combo may incr. risk of serious infection, myelosuppression (additive effects)

  • enfortumab vedotin
  • Lifyorli (relacorilant)
    +
    enfortumab vedotin
    1 interaction

    Monitor/Modify Tx

    relacorilant + enfortumab vedotin

    if also combined with P-gp inhibitor, monitor CBC, glucose: combo may incr. enfortumab vedotin levels, risk of myelosuppression, neuropathy, hyperglycemia, other adverse effects (hepatic metabolism inhibited)

  • erythromycin
  • Lifyorli (relacorilant)
    +
    erythromycin
    1 interaction

    Monitor/Modify Tx

    relacorilant + erythromycin

    monitor ECG: combo may incr. erythromycin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • esomeprazole
  • Lifyorli (relacorilant)
    +
    esomeprazole
    1 interaction

    Monitor/Modify Tx

    relacorilant + esomeprazole

    consider decr. esomeprazole dose if hypersecretory condition tx; otherwise, caution advised: combo may incr. esomeprazole levels, risk of adverse effects (hepatic metabolism inhibited)

  • estradiol (contraceptive)
  • Lifyorli (relacorilant)
    +
    estradiol (contraceptive)
    1 interaction

    Monitor/Modify Tx

    relacorilant + estradiol (contraceptive)

    monitor thrombosis signs/symptoms: combo may incr. estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited)

  • eszopiclone
  • Lifyorli (relacorilant)
    +
    eszopiclone
    1 interaction

    Monitor/Modify Tx

    relacorilant + eszopiclone

    adjust eszopiclone max dose to 2 mg/day: combo may incr. eszopiclone levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • etuvetidigene autotemcel
  • Lifyorli (relacorilant)
    +
    etuvetidigene autotemcel
    1 interaction

    Monitor/Modify Tx

    relacorilant + etuvetidigene autotemcel

    monitor CBC, bleeding s/sx: combo may incr. risk of serious infection, myelosuppression, bleeding (additive effects)

  • exagamglogene autotemcel
  • Lifyorli (relacorilant)
    +
    exagamglogene autotemcel
    1 interaction

    Monitor/Modify Tx

    relacorilant + exagamglogene autotemcel

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

  • felodipine
  • Lifyorli (relacorilant)
    +
    felodipine
    1 interaction

    Monitor/Modify Tx

    relacorilant + felodipine

    monitor BP, HR: combo may incr. felodipine levels, risk of hypotension, reflex tachycardia, other adverse effects (hepatic metabolism inhibited)

  • filgrastim (G-CSF)
  • Lifyorli (relacorilant)
    +
    filgrastim (G-CSF)
    1 interaction

    Monitor/Modify Tx

    relacorilant + filgrastim (G-CSF)

    give filgrastim at least 24h before or after myelosuppressive chemo: combo may decr. filgrastim efficacy (antagonistic effects)

  • flucytosine
  • Lifyorli (relacorilant)
    +
    flucytosine
    1 interaction

    Monitor/Modify Tx

    relacorilant + flucytosine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • fluphenazine
  • Lifyorli (relacorilant)
    +
    fluphenazine
    1 interaction

    Monitor/Modify Tx

    relacorilant + fluphenazine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • foscarnet
  • Lifyorli (relacorilant)
    +
    foscarnet
    1 interaction

    Monitor/Modify Tx

    relacorilant + foscarnet

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • fosfomycin injection
  • Lifyorli (relacorilant)
    +
    fosfomycin injection
    1 interaction

    Monitor/Modify Tx

    relacorilant + fosfomycin injection

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • fostamatinib
  • Lifyorli (relacorilant)
    +
    fostamatinib
    1 interaction

    Monitor/Modify Tx

    relacorilant + fostamatinib

    monitor BP, CBC, LFTs, consider decr. fostamatinib dose: combo may incr. fostamatinib active metabolite levels, risk of HTN, myelosuppression, hepatotoxicity, other adverse effects (hepatic metabolism inhibited, additive effects)

  • givinostat
  • Lifyorli (relacorilant)
    +
    givinostat
    1 interaction

    Monitor/Modify Tx

    relacorilant + givinostat

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • guanfacine
  • Lifyorli (relacorilant)
    +
    guanfacine
    1 interaction

    Monitor/Modify Tx

    relacorilant + guanfacine

    decr. guanfacine ER dose 50%, consider decr. dose for immed.-release form: combo may incr. guanfacine levels, risk of adverse effects (hepatic metabolism inhibited)

  • Haemophilus b vaccine
  • Lifyorli (relacorilant)
    +
    Haemophilus b vaccine
    1 interaction

    Monitor/Modify Tx

    relacorilant + Haemophilus b vaccine

    if possible, vaccinate at least 2wk before relacorilant start; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

  • haloperidol
  • Lifyorli (relacorilant)
    +
    haloperidol
    1 interaction

    Monitor/Modify Tx

    relacorilant + haloperidol

    monitor ECG; consider decr. haloperidol dose: combo may incr. haloperidol levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • hepatitis A vaccine
  • Lifyorli (relacorilant)
    +
    hepatitis A vaccine
    1 interaction

    Monitor/Modify Tx

    relacorilant + hepatitis A vaccine

    if possible, vaccinate at least 2wk before relacorilant start; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

  • hepatitis B vaccine
  • Lifyorli (relacorilant)
    +
    hepatitis B vaccine
    1 interaction

    Monitor/Modify Tx

    relacorilant + hepatitis B vaccine

    if possible, vaccinate at least 2wk before relacorilant start; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

  • human papillomavirus vaccine
  • Lifyorli (relacorilant)
    +
    human papillomavirus vaccine
    1 interaction

    Monitor/Modify Tx

    relacorilant + human papillomavirus vaccine

    if possible, vaccinate at least 2wk before relacorilant start; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

  • hydroxychloroquine
  • Lifyorli (relacorilant)
    +
    hydroxychloroquine
    1 interaction

    Monitor/Modify Tx

    relacorilant + hydroxychloroquine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • hydroxyurea
  • Lifyorli (relacorilant)
    +
    hydroxyurea
    1 interaction

    Monitor/Modify Tx

    relacorilant + hydroxyurea

    monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

  • ibrexafungerp
  • Lifyorli (relacorilant)
    +
    ibrexafungerp
    1 interaction

    Monitor/Modify Tx

    relacorilant + ibrexafungerp

    decr. ibrexafungerp dose to 150 mg q12h: combo may incr. ibrexafungerp levels, risk of adverse effects (hepatic metabolism inhibited)

  • iloperidone
  • Lifyorli (relacorilant)
    +
    iloperidone
    1 interaction

    Monitor/Modify Tx

    relacorilant + iloperidone

    monitor ECG; decr. iloperidone dose 50%: combo may incr. iloperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • imatinib
  • Lifyorli (relacorilant)
    +
    imatinib
    1 interaction

    Monitor/Modify Tx

    relacorilant + imatinib

    monitor CBC: combo may incr. imatinib levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • influenza H5N1 vaccine
  • Lifyorli (relacorilant)
    +
    influenza H5N1 vaccine
    1 interaction

    Monitor/Modify Tx

    relacorilant + influenza H5N1 vaccine

    if possible, vaccinate at least 2wk before relacorilant start; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

  • influenza vaccine
  • Lifyorli (relacorilant)
    +
    influenza vaccine
    1 interaction

    Monitor/Modify Tx

    relacorilant + influenza vaccine

    if possible, vaccinate at least 2wk before relacorilant start; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

  • interferon beta 1a
  • Lifyorli (relacorilant)
    +
    interferon beta 1a
    1 interaction

    Monitor/Modify Tx

    relacorilant + interferon beta 1a

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • interferon beta 1b
  • Lifyorli (relacorilant)
    +
    interferon beta 1b
    1 interaction

    Monitor/Modify Tx

    relacorilant + interferon beta 1b

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • interferon gamma 1b
  • Lifyorli (relacorilant)
    +
    interferon gamma 1b
    1 interaction

    Monitor/Modify Tx

    relacorilant + interferon gamma 1b

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • istradefylline
  • Lifyorli (relacorilant)
    +
    istradefylline
    1 interaction

    Monitor/Modify Tx

    relacorilant + istradefylline

    adjust max istradefylline dose to 20 mg/day: combo may incr. istradefylline levels, risk of adverse effects (hepatic metabolism inhibited)

  • itraconazole
  • Lifyorli (relacorilant)
    +
    itraconazole
    1 interaction

    Monitor/Modify Tx

    relacorilant + itraconazole

    consider decr. itraconazole dose: combo may incr. itraconazole levels, risk of adverse effects (hepatic metabolism inhibited)

  • Japanese encephalitis vaccine
  • Lifyorli (relacorilant)
    +
    Japanese encephalitis vaccine
    1 interaction

    Monitor/Modify Tx

    relacorilant + Japanese encephalitis vaccine

    if possible, vaccinate at least 2wk before relacorilant start; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

  • ketoconazole
  • Lifyorli (relacorilant)
    +
    ketoconazole
    1 interaction

    Monitor/Modify Tx

    relacorilant + ketoconazole

    consider decr. ketoconazole dose: combo may incr. ketoconazole levels, risk of adverse effects (hepatic metabolism inhibited)

  • lacosamide
  • Lifyorli (relacorilant)
    +
    lacosamide
    1 interaction

    Monitor/Modify Tx

    relacorilant + lacosamide

    monitor HR; consider decr. lacosamide dose if also renal or hepatic impairment: combo may incr. lacosamide levels, risk of bradycardia, CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • leflunomide
  • Lifyorli (relacorilant)
    +
    leflunomide
    1 interaction

    Monitor/Modify Tx

    relacorilant + leflunomide

    monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

  • levomilnacipran
  • Lifyorli (relacorilant)
    +
    levomilnacipran
    1 interaction

    Monitor/Modify Tx

    relacorilant + levomilnacipran

    adjust max levomilnacipran dose to 80 mg/day: combo may incr. levomilnacipran levels, adverse effects (hepatic metabolism inhibited)

  • lidocaine
  • Lifyorli (relacorilant)
    +
    lidocaine
    1 interaction

    Monitor/Modify Tx

    relacorilant + lidocaine

    monitor lidocaine levels if lidocaine antiarrhythmic use; otherwise, monitor BP, HR: combo may incr. lidocaine levels, risk of hypotension, bradycardia, other adverse effects; risk may be higher with continuous infusion or higher doses for local anesthesia (hepatic metabolism inhibited)

  • linezolid
  • Lifyorli (relacorilant)
    +
    linezolid
    1 interaction

    Monitor/Modify Tx

    relacorilant + linezolid

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • loperamide
  • Lifyorli (relacorilant)
    +
    loperamide
    1 interaction

    Monitor/Modify Tx

    relacorilant + loperamide

    monitor ECG, especially if also combined with CYP2C8, P-gp inhibitors or if loperamide dose >16mg/day: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • lovotibeglogene autotemcel
  • Lifyorli (relacorilant)
    +
    lovotibeglogene autotemcel
    1 interaction

    Monitor/Modify Tx

    relacorilant + lovotibeglogene autotemcel

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

  • lumateperone
  • Lifyorli (relacorilant)
    +
    lumateperone
    1 interaction

    Monitor/Modify Tx

    relacorilant + lumateperone

    monitor ECG; decr. lumateperone dose to 10.5 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • lymphocyte immune globulin, anti-thymocyte globulin
  • Lifyorli (relacorilant)
    +
    lymphocyte immune globulin, anti-thymocyte globulin
    1 interaction

    Monitor/Modify Tx

    relacorilant + lymphocyte immune globulin, anti-thymocyte globulin

    monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

  • maraviroc
  • Lifyorli (relacorilant)
    +
    maraviroc
    1 interaction

    Monitor/Modify Tx

    relacorilant + maraviroc

    ADULTS: adjust maraviroc dose to 150 mg bid, even if also combined w/ potent CYP3A4 inducer; PEDS: see maraviroc pkg insert for age/wt-based dose adjustments: combo may incr. maraviroc levels, risk of adverse effects (hepatic metabolism inhibited)

  • marnetegragene autotemcel
  • Lifyorli (relacorilant)
    +
    marnetegragene autotemcel
    1 interaction

    Monitor/Modify Tx

    relacorilant + marnetegragene autotemcel

    monitor CBC, bleeding signs/symptoms: combo may incr. risk of serious infection, myelosuppression (additive effects)

  • mavacamten
  • Lifyorli (relacorilant)
    +
    mavacamten
    1 interaction

    Monitor/Modify Tx

    relacorilant + mavacamten

    monitor cardiac fxn, incl. LVEF; if pt stable on relacorilant tx, initiate mavacamten at 2.5 mg qd; if adding short-term (<1wk) relacorilant tx to existing mavacamten tx, hold mavacamten until relacorilant D/C; if adding longer-term (>1wk) relacorilant tx, decr. mavacamten dose as follows for at least 12wk: decr. mavacamten 15 mg qd to 10 mg qd; decr. mavacamten 10 mg qd to 5 mg qd; decr. mavacamten 5 mg qd to 2.5 mg qd; do not start relacorilant tx if on mavacamten 2.5 mg qd: combo may incr. mavacamten levels, risk of heart failure, other adverse effects; may decr. relacorilant levels, efficacy (hepatic metabolism inhibited; hepatic metabolism possibly induced)

  • mavorixafor
  • Lifyorli (relacorilant)
    +
    mavorixafor
    1 interaction

    Monitor/Modify Tx

    relacorilant + mavorixafor

    decr. mavorixafor dose to 200 mg qd: combo may incr. mavorixafor levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • meningococcal vaccine
  • Lifyorli (relacorilant)
    +
    meningococcal vaccine
    1 interaction

    Monitor/Modify Tx

    relacorilant + meningococcal vaccine

    if possible, vaccinate at least 2wk before relacorilant start; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

  • mercaptopurine
  • Lifyorli (relacorilant)
    +
    mercaptopurine
    1 interaction

    Monitor/Modify Tx

    relacorilant + mercaptopurine

    monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

  • mesalamine
  • Lifyorli (relacorilant)
    +
    mesalamine
    1 interaction

    Monitor/Modify Tx

    relacorilant + mesalamine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • mesalamine rectal
  • Lifyorli (relacorilant)
    +
    mesalamine rectal
    1 interaction

    Monitor/Modify Tx

    relacorilant + mesalamine rectal

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • methotrexate
  • Lifyorli (relacorilant)
    +
    methotrexate
    1 interaction

    Monitor/Modify Tx

    relacorilant + methotrexate

    monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

  • milsaperidone
  • Lifyorli (relacorilant)
    +
    milsaperidone
    1 interaction

    Monitor/Modify Tx

    relacorilant + milsaperidone

    monitor ECG; decr. milsaperidone maintenance dose 50%: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • mirtazapine
  • Lifyorli (relacorilant)
    +
    mirtazapine
    1 interaction

    Monitor/Modify Tx

    relacorilant + mirtazapine

    monitor ECG: combo may incr. mirtazapine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • mycophenolate mofetil
  • Lifyorli (relacorilant)
    +
    mycophenolate mofetil
    1 interaction

    Monitor/Modify Tx

    relacorilant + mycophenolate mofetil

    monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

  • mycophenolic acid
  • Lifyorli (relacorilant)
    +
    mycophenolic acid
    1 interaction

    Monitor/Modify Tx

    relacorilant + mycophenolic acid

    monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

  • nerandomilast
  • Lifyorli (relacorilant)
    +
    nerandomilast
    1 interaction

    Monitor/Modify Tx

    relacorilant + nerandomilast

    decr. nerandomilast dose to 9 mg twice daily: combo may incr. nerandomilast levels, risk of adverse effects (hepatic metabolism inhibited)

  • nicardipine
  • Lifyorli (relacorilant)
    +
    nicardipine
    1 interaction

    Monitor/Modify Tx

    relacorilant + nicardipine

    monitor BP: combo may incr. or decr. nicardipine levels, incr. risk of hypotension, other adverse effects or decr. efficacy (hepatic metabolism altered)

  • nifedipine
  • Lifyorli (relacorilant)
    +
    nifedipine
    1 interaction

    Monitor/Modify Tx

    relacorilant + nifedipine

    monitor BP, consider lowest nifedipine start dose: combo may incr. nifedipine levels, risk of hypotension, other adverse effects (hepatic metabolism inhibited)

  • nintedanib
  • Lifyorli (relacorilant)
    +
    nintedanib
    1 interaction

    Monitor/Modify Tx

    relacorilant + nintedanib

    consider decr. nintedanib dose: combo may incr. nintedanib levels, risk of adverse effects (hepatic metabolism inhibited)

  • nortriptyline
  • Lifyorli (relacorilant)
    +
    nortriptyline
    1 interaction

    Monitor/Modify Tx

    relacorilant + nortriptyline

    monitor nortriptyline levels: combo may incr. nortriptyline levels, risk of adverse effects (hepatic metabolism inhibited)

  • olsalazine
  • Lifyorli (relacorilant)
    +
    olsalazine
    1 interaction

    Monitor/Modify Tx

    relacorilant + olsalazine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • omeprazole
  • Lifyorli (relacorilant)
    +
    omeprazole
    1 interaction

    Monitor/Modify Tx

    relacorilant + omeprazole

    consider decr. omeprazole dose if hypersecretory condition tx; otherwise, caution advised: combo may incr. omeprazole levels, risk of adverse effects (hepatic metabolism inhibited)

  • osilodrostat
  • Lifyorli (relacorilant)
    +
    osilodrostat
    1 interaction

    Monitor/Modify Tx

    relacorilant + osilodrostat

    monitor ECG; decr. osilodrostat dose by 50%: combo may incr. osilodrostat levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • paclitaxel
  • Lifyorli (relacorilant)
    +
    paclitaxel
    1 interaction

    Monitor/Modify Tx

    relacorilant + paclitaxel

    monitor CBC: combo may incr. paclitaxel levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

  • paricalcitol
  • Lifyorli (relacorilant)
    +
    paricalcitol
    1 interaction

    Monitor/Modify Tx

    relacorilant + paricalcitol

    monitor calcium, iPTH, adjust paricalcitol dose: combo may incr. paricalcitol levels, risk of hypercalcemia, other adverse effects (hepatic metabolism inhibited)

  • pegfilgrastim (G-CSF)
  • Lifyorli (relacorilant)
    +
    pegfilgrastim (G-CSF)
    1 interaction

    Monitor/Modify Tx

    relacorilant + pegfilgrastim (G-CSF)

    give pegfilgrastim >24h after or >14 days before myelosuppressive chemo: combo may decr. pegfilgrastim efficacy (antagonistic effects)

  • peginterferon alfa 2a
  • Lifyorli (relacorilant)
    +
    peginterferon alfa 2a
    1 interaction

    Monitor/Modify Tx

    relacorilant + peginterferon alfa 2a

    monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

  • peginterferon beta 1a
  • Lifyorli (relacorilant)
    +
    peginterferon beta 1a
    1 interaction

    Monitor/Modify Tx

    relacorilant + peginterferon beta 1a

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • pentamidine
  • Lifyorli (relacorilant)
    +
    pentamidine
    1 interaction

    Monitor/Modify Tx

    relacorilant + pentamidine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • pimavanserin
  • Lifyorli (relacorilant)
    +
    pimavanserin
    1 interaction

    Monitor/Modify Tx

    relacorilant + pimavanserin

    monitor ECG; decr. pimavanserin dose to 10 mg qd: combo may incr. pimavanserin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • pneumococcal vaccine
  • Lifyorli (relacorilant)
    +
    pneumococcal vaccine
    1 interaction

    Monitor/Modify Tx

    relacorilant + pneumococcal vaccine

    if possible, vaccinate at least 2wk before relacorilant start; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

  • polatuzumab vedotin
  • Lifyorli (relacorilant)
    +
    polatuzumab vedotin
    1 interaction

    Monitor/Modify Tx

    relacorilant + polatuzumab vedotin

    monitor CBC, LFTs: combo may incr. polatuzumab vedotin levels, risk of serious infection, myelosuppression, peripheral neuropathy, hepatotoxicity, other adverse effects (hepatic metabolism inhibited, additive effects)

  • poliovirus vaccine
  • Lifyorli (relacorilant)
    +
    poliovirus vaccine
    1 interaction

    Monitor/Modify Tx

    relacorilant + poliovirus vaccine

    if possible, vaccinate at least 2wk before relacorilant start; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

  • proguanil
  • Lifyorli (relacorilant)
    +
    proguanil
    1 interaction

    Monitor/Modify Tx

    relacorilant + proguanil

    monitor CBC, especially if concomitant renal impairment: combo may incr. risk of myelosuppression (additive effects)

  • pyrimethamine
  • Lifyorli (relacorilant)
    +
    pyrimethamine
    1 interaction

    Monitor/Modify Tx

    relacorilant + pyrimethamine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • quetiapine
  • Lifyorli (relacorilant)
    +
    quetiapine
    1 interaction

    Monitor/Modify Tx

    relacorilant + quetiapine

    decr. quetiapine to 1/6th of original dose: combo may incr. quetiapine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • quinidine (antiarrhythmic)
  • Lifyorli (relacorilant)
    +
    quinidine (antiarrhythmic)
    1 interaction

    Monitor/Modify Tx

    relacorilant + quinidine (antiarrhythmic)

    monitor quinidine levels, ECG: combo may incr. quinidine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • quinidine (CYP2D6 inhibitor)
  • Lifyorli (relacorilant)
    +
    quinidine (CYP2D6 inhibitor)
    1 interaction

    Monitor/Modify Tx

    relacorilant + quinidine (CYP2D6 inhibitor)

    monitor ECG: combo may incr. quinidine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • quinine
  • Lifyorli (relacorilant)
    +
    quinine
    1 interaction

    Monitor/Modify Tx

    relacorilant + quinine

    monitor ECG: combo may incr. quinine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • repaglinide
  • Lifyorli (relacorilant)
    +
    repaglinide
    1 interaction

    Monitor/Modify Tx

    relacorilant + repaglinide

    monitor glucose: combo may incr. repaglinide levels, risk of hypoglycemia, other adverse effects (hepatic metabolism inhibited)

  • respiratory syncytial virus vaccine
  • Lifyorli (relacorilant)
    +
    respiratory syncytial virus vaccine
    1 interaction

    Monitor/Modify Tx

    relacorilant + respiratory syncytial virus vaccine

    if possible, vaccinate at least 2wk before relacorilant start; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

  • revumenib
  • Lifyorli (relacorilant)
    +
    revumenib
    1 interaction

    Monitor/Modify Tx

    relacorilant + revumenib

    monitor ECG, electrolytes; WEIGHT 40 KG OR MORE: decr. revumenib dose to 160 mg bid; WEIGHT <40 KG: decr. revumenib dose to 95 mg/m^2 bid: combo may incr. revumenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • ribavirin
  • Lifyorli (relacorilant)
    +
    ribavirin
    1 interaction

    Monitor/Modify Tx

    relacorilant + ribavirin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • rilpivirine
  • Lifyorli (relacorilant)
    +
    rilpivirine
    1 interaction

    Monitor/Modify Tx

    relacorilant + rilpivirine

    monitor ECG: combo may incr. rilpivirine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • riociguat
  • Lifyorli (relacorilant)
    +
    riociguat
    1 interaction

    Monitor/Modify Tx

    relacorilant + riociguat

    consider decr. riociguat start dose to 0.5 mg PO tid; monitor BP: combo may incr. riociguat levels, risk of severe hypotension, other adverse effects (hepatic metabolism inhibited)

  • rituximab
  • Lifyorli (relacorilant)
    +
    rituximab
    1 interaction

    Monitor/Modify Tx

    relacorilant + rituximab

    monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

  • romidepsin
  • Lifyorli (relacorilant)
    +
    romidepsin
    1 interaction

    Monitor/Modify Tx

    relacorilant + romidepsin

    monitor ECG, CBC; consider romidepsin dose adjustment: combo may incr. romidepsin levels, risk of QT prolongation, cardiac arrhythmias, serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

  • sargramostim (GM-CSF)
  • Lifyorli (relacorilant)
    +
    sargramostim (GM-CSF)
    1 interaction

    Monitor/Modify Tx

    relacorilant + sargramostim (GM-CSF)

    give sargramostim at least 24h before or after myelosuppressive chemo: combo may decr. sargramostim efficacy (antagonistic effects)

  • sarilumab
  • Lifyorli (relacorilant)
    +
    sarilumab
    1 interaction

    Monitor/Modify Tx

    relacorilant + sarilumab

    monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

  • satralizumab
  • Lifyorli (relacorilant)
    +
    satralizumab
    1 interaction

    Monitor/Modify Tx

    relacorilant + satralizumab

    monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

  • saxagliptin
  • Lifyorli (relacorilant)
    +
    saxagliptin
    1 interaction

    Monitor/Modify Tx

    relacorilant + saxagliptin

    monitor glucose; adjust max saxagliptin dose to 2.5 mg/day: combo may incr. saxagliptin levels, risk of hypoglycemia, other adverse effects (hepatic metabolism inhibited)

  • sertraline
  • Lifyorli (relacorilant)
    +
    sertraline
    1 interaction

    Monitor/Modify Tx

    relacorilant + sertraline

    monitor ECG: combo may incr. sertraline levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • smallpox/mpox vaccine, live
  • Lifyorli (relacorilant)
    +
    smallpox/ mpox vaccine, live
    1 interaction

    Monitor/Modify Tx

    relacorilant + smallpox/ mpox vaccine, live

    consider vaccinating at least 4wk before or 3mo after relacorilant use: combo may result in inadequate vaccine response (immunosuppressive effects)

  • solifenacin
  • Lifyorli (relacorilant)
    +
    solifenacin
    1 interaction

    Monitor/Modify Tx

    relacorilant + solifenacin

    monitor ECG; adjust solifenacin dose as follows: pts 9-15 kg: max 2 mg/day; pts 16-45 kg: max 3 mg/day; pts 46-60 kg: max 4 mg/day; pts >60 kg or adult pts: max 5 mg/day: combo may incr. solifenacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • stiripentol
  • Lifyorli (relacorilant)
    +
    stiripentol
    1 interaction

    Monitor/Modify Tx

    relacorilant + stiripentol

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • succimer
  • Lifyorli (relacorilant)
    +
    succimer
    1 interaction

    Monitor/Modify Tx

    relacorilant + succimer

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • sulfasalazine
  • Lifyorli (relacorilant)
    +
    sulfasalazine
    1 interaction

    Monitor/Modify Tx

    relacorilant + sulfasalazine

    monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

  • tacrolimus
  • Lifyorli (relacorilant)
    +
    tacrolimus
    1 interaction

    Monitor/Modify Tx

    relacorilant + tacrolimus

    monitor tacrolimus levels, ECG, renal fxn: combo may incr. tacrolimus levels, risk of QT prolongation, cardiac arrhythmias, serious infection, nephrotoxicity, other adverse effects (hepatic metabolism inhibited, additive effects)

  • teplizumab
  • Lifyorli (relacorilant)
    +
    teplizumab
    1 interaction

    Monitor/Modify Tx

    relacorilant + teplizumab

    monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

  • teriflunomide
  • Lifyorli (relacorilant)
    +
    teriflunomide
    1 interaction

    Monitor/Modify Tx

    relacorilant + teriflunomide

    monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

  • tezacaftor/ivacaftor
  • Lifyorli (relacorilant)
    +
    tezacaftor/ ivacaftor
    1 interaction

    Monitor/Modify Tx

    relacorilant + tezacaftor/ ivacaftor

    decr. tezacaftor/ivacaftor morning dose to 2x/wk (3-4 days apart), no ivacaftor evening doses: combo may incr. tezacaftor/ivacaftor levels, risk of adverse effects (hepatic metabolism inhibited)

  • thalidomide
  • Lifyorli (relacorilant)
    +
    thalidomide
    1 interaction

    Monitor/Modify Tx

    relacorilant + thalidomide

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • theophylline
  • Lifyorli (relacorilant)
    +
    theophylline
    1 interaction

    Monitor/Modify Tx

    relacorilant + theophylline

    monitor theophylline levels: combo may incr. theophylline levels, risk of cardiac arrhythmias, seizures, other toxicities (hepatic metabolism inhibited)

  • tick-borne encephalitis vaccine
  • Lifyorli (relacorilant)
    +
    tick-borne encephalitis vaccine
    1 interaction

    Monitor/Modify Tx

    relacorilant + tick-borne encephalitis vaccine

    if possible, vaccinate at least 2wk before relacorilant start; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

  • tocilizumab
  • Lifyorli (relacorilant)
    +
    tocilizumab
    1 interaction

    Monitor/Modify Tx

    relacorilant + tocilizumab

    monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

  • tofacitinib
  • Lifyorli (relacorilant)
    +
    tofacitinib
    1 interaction

    Monitor/Modify Tx

    relacorilant + tofacitinib

    ALL USES: monitor CBC; ADULT RHEUMATOID or PSORIATIC ARTHRITIS or ANKYLOSING SPONDYLITIS: decr. tofacitinib dose to 5 mg qd; ADULT ULCERATIVE COLITIS: decr. tofacitinib induction to 5 mg tablet bid or 11 mg XR tablet qd for up to 16 wks, then 5 mg tablet qd maintenance; do not use XR tablet for maintenance; PEDIATRIC PSORIATIC ARTHRITIS, POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS: decr. usual tofacitinib bid dose to qd: combo may incr. tofacitinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

  • tolterodine
  • Lifyorli (relacorilant)
    +
    tolterodine
    1 interaction

    Monitor/Modify Tx

    relacorilant + tolterodine

    adjust tolterodine dose to max 2 mg/day: combo may incr. tolterodine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • trimethoprim
  • Lifyorli (relacorilant)
    +
    trimethoprim
    1 interaction

    Monitor/Modify Tx

    relacorilant + trimethoprim

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • typhoid vaccine
  • Lifyorli (relacorilant)
    +
    typhoid vaccine
    1 interaction

    Monitor/Modify Tx

    relacorilant + typhoid vaccine

    if possible, vaccinate at least 2wk before relacorilant start; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

  • upadacitinib
  • Lifyorli (relacorilant)
    +
    upadacitinib
    1 interaction

    Monitor/Modify Tx

    relacorilant + upadacitinib

    monitor CBC; ATOPIC DERMATITIS: limit upadacitinib dose to 15 mg qd; CROHN DZ: limit upadacitinib induction dose to 30 mg qd x12wk, followed by 15 mg qd maintenance; ULCERATIVE COLITIS: limit upadacitinib induction dose to 30 mg qd x8wk, followed by 15 mg qd maintenance; ALL OTHER INDICATIONS: no dose adjustment: combo may incr. upadacitinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

  • valbenazine
  • Lifyorli (relacorilant)
    +
    valbenazine
    1 interaction

    Monitor/Modify Tx

    relacorilant + valbenazine

    monitor ECG; decr. valbenazine dose to 40 mg qd: combo may incr. valbenazine and active metabolite levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • valproic acid
  • Lifyorli (relacorilant)
    +
    valproic acid
    1 interaction

    Monitor/Modify Tx

    relacorilant + valproic acid

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • vancomycin
  • Lifyorli (relacorilant)
    +
    vancomycin
    1 interaction

    Monitor/Modify Tx

    relacorilant + vancomycin

    VANCOMYCIN IV: monitor CBC, especially w/ long-term vancomycin; VANCOMYCIN PO use OK: combo may incr. risk of myelosuppression (additive effects)

  • vanzacaftor/tezacaftor/deutivacaftor
  • Lifyorli (relacorilant)
    +
    vanzacaftor/ tezacaftor/ deutivacaftor
    1 interaction

    Monitor/Modify Tx

    relacorilant + vanzacaftor/ tezacaftor/ deutivacaftor

    6-11 YO AND WT <40 KG: decr. vanzacaftor/tezacaftor/deutivacaftor dose to two tablets (4 mg/20 mg/50 mg each) qwk; 6-11 YO AND WT 40 KG AND ABOVE: decr. vanzacaftor/tezacaftor/deutivacaftor dose to one tablet (10 mg/50 mg/125 mg) qwk; 12 YO AND OLDER: decr. vanzacaftor/tezacaftor/deutivacaftor dose to one tablet (10 mg/50 mg/125 mg) qwk: combo may incr. vanzacaftor/tezacaftor/deutivacaftor levels, risk of adverse effects (hepatic metabolism inhibited)

  • verapamil
  • Lifyorli (relacorilant)
    +
    verapamil
    1 interaction

    Monitor/Modify Tx

    relacorilant + verapamil

    monitor BP, HR: combo may incr. or decr. verapamil levels, incr. risk of hypotension, bradycardia, AV block, other adverse effects or decr. efficacy (hepatic metabolism altered)

  • vilanterol inhaled
  • Lifyorli (relacorilant)
    +
    vilanterol inhaled
    1 interaction

    Monitor/Modify Tx

    relacorilant + vilanterol inhaled

    monitor BP, HR: combo may incr. vilanterol exposure, risk of HTN, tachycardia, other adverse effects (hepatic metabolism inhibited)

  • vilazodone
  • Lifyorli (relacorilant)
    +
    vilazodone
    1 interaction

    Monitor/Modify Tx

    relacorilant + vilazodone

    adjust max vilazodone dose to 20 mg/day: combo may incr. vilazodone levels, risk of adverse effects (hepatic metabolism inhibited)

  • voriconazole
  • Lifyorli (relacorilant)
    +
    voriconazole
    1 interaction

    Monitor/Modify Tx

    relacorilant + voriconazole

    monitor ECG: combo may incr. voriconazole levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • warfarin
  • Lifyorli (relacorilant)
    +
    warfarin
    1 interaction

    Monitor/Modify Tx

    relacorilant + warfarin

    monitor INR, bleeding s/sx, especially during initiation/titration: combo may incr. warfarin levels, risk of bleeding (incl. life-threatening), other adverse effects (hepatic metabolism inhibited)

  • zanubrutinib
  • Lifyorli (relacorilant)
    +
    zanubrutinib
    1 interaction

    Monitor/Modify Tx

    relacorilant + zanubrutinib

    decr. zanubrutinib dose to 80 mg qd; monitor CBC: combo may incr. zanubrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

  • zidovudine
  • Lifyorli (relacorilant)
    +
    zidovudine
    1 interaction

    Monitor/Modify Tx

    relacorilant + zidovudine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • ziftomenib
  • Lifyorli (relacorilant)
    +
    ziftomenib
    1 interaction

    Monitor/Modify Tx

    relacorilant + ziftomenib

    monitor ECG: combo may incr. ziftomenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • zolpidem
  • Lifyorli (relacorilant)
    +
    zolpidem
    1 interaction

    Monitor/Modify Tx

    relacorilant + zolpidem

    consider decr. zolpidem dose: combo may incr. zolpidem levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • zuranolone
  • Lifyorli (relacorilant)
    +
    zuranolone
    1 interaction

    Monitor/Modify Tx

    relacorilant + zuranolone

    decr. zuranolone dose to 30 mg qd: combo may incr. zuranolone levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

Caution Advised

  • abatacept
  • Lifyorli (relacorilant)
    +
    abatacept
    1 interaction

    Caution Advised

    relacorilant + abatacept

    caution advised: combo may incr. risk of serious infection (additive effects)

  • abrocitinib
  • Lifyorli (relacorilant)
    +
    abrocitinib
    1 interaction

    Caution Advised

    relacorilant + abrocitinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • adalimumab
  • Lifyorli (relacorilant)
    +
    adalimumab
    1 interaction

    Caution Advised

    relacorilant + adalimumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • afamitresgene autoleucel
  • Lifyorli (relacorilant)
    +
    afamitresgene autoleucel
    1 interaction

    Caution Advised

    relacorilant + afamitresgene autoleucel

    caution advised: combo may incr. risk of serious infection (additive effects)

  • aldesleukin
  • Lifyorli (relacorilant)
    +
    aldesleukin
    1 interaction

    Caution Advised

    relacorilant + aldesleukin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • aliskiren
  • Lifyorli (relacorilant)
    +
    aliskiren
    1 interaction

    Caution Advised

    relacorilant + aliskiren

    caution advised: combo may incr. aliskiren levels, risk of adverse effects (hepatic metabolism inhibited)

  • alosetron
  • Lifyorli (relacorilant)
    +
    alosetron
    1 interaction

    Caution Advised

    relacorilant + alosetron

    caution advised: combo may incr. alosetron levels, risk of adverse effects (hepatic metabolism inhibited)

  • anakinra
  • Lifyorli (relacorilant)
    +
    anakinra
    1 interaction

    Caution Advised

    relacorilant + anakinra

    caution advised: combo may incr. risk of serious infection (additive effects)

  • anifrolumab
  • Lifyorli (relacorilant)
    +
    anifrolumab
    1 interaction

    Caution Advised

    relacorilant + anifrolumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • armodafinil
  • Lifyorli (relacorilant)
    +
    armodafinil
    1 interaction

    Caution Advised

    relacorilant + armodafinil

    caution advised: combo may incr. armodafinil levels, risk of adverse effects (hepatic metabolism inhibited)

  • axicabtagene ciloleucel
  • Lifyorli (relacorilant)
    +
    axicabtagene ciloleucel
    1 interaction

    Caution Advised

    relacorilant + axicabtagene ciloleucel

    caution advised: combo may incr. risk of serious infection (additive effects)

  • azacitidine
  • Lifyorli (relacorilant)
    +
    azacitidine
    1 interaction

    Caution Advised

    relacorilant + azacitidine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • basiliximab
  • Lifyorli (relacorilant)
    +
    basiliximab
    1 interaction

    Caution Advised

    relacorilant + basiliximab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • beclomethasone inhaled
  • Lifyorli (relacorilant)
    +
    beclomethasone inhaled
    1 interaction

    Caution Advised

    relacorilant + beclomethasone inhaled

    caution advised: combo may incr. risk of serious infection (additive effects)

  • beclomethasone nasal
  • Lifyorli (relacorilant)
    +
    beclomethasone nasal
    1 interaction

    Caution Advised

    relacorilant + beclomethasone nasal

    caution advised: combo may incr. risk of serious infection (additive effects)

  • belatacept
  • Lifyorli (relacorilant)
    +
    belatacept
    1 interaction

    Caution Advised

    relacorilant + belatacept

    caution advised: combo may incr. risk of serious infection (additive effects)

  • belimumab
  • Lifyorli (relacorilant)
    +
    belimumab
    1 interaction

    Caution Advised

    relacorilant + belimumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • belinostat
  • Lifyorli (relacorilant)
    +
    belinostat
    1 interaction

    Caution Advised

    relacorilant + belinostat

    caution advised: combo may incr. risk of serious infection (additive effects)

  • bendamustine
  • Lifyorli (relacorilant)
    +
    bendamustine
    1 interaction

    Caution Advised

    relacorilant + bendamustine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • bictegravir
  • Lifyorli (relacorilant)
    +
    bictegravir
    1 interaction

    Caution Advised

    relacorilant + bictegravir

    caution advised if also combined w/ UGT1A1 inhibitor: combo may incr. bictegravir levels, risk of adverse effects (hepatic metabolism inhibited)

  • bimekizumab
  • Lifyorli (relacorilant)
    +
    bimekizumab
    1 interaction

    Caution Advised

    relacorilant + bimekizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • blinatumomab
  • Lifyorli (relacorilant)
    +
    blinatumomab
    1 interaction

    Caution Advised

    relacorilant + blinatumomab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • brexucabtagene autoleucel
  • Lifyorli (relacorilant)
    +
    brexucabtagene autoleucel
    1 interaction

    Caution Advised

    relacorilant + brexucabtagene autoleucel

    caution advised: combo may incr. risk of serious infection (additive effects)

  • brodalumab
  • Lifyorli (relacorilant)
    +
    brodalumab
    1 interaction

    Caution Advised

    relacorilant + brodalumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • budesonide inhaled
  • Lifyorli (relacorilant)
    +
    budesonide inhaled
    1 interaction

    Caution Advised

    relacorilant + budesonide inhaled

    caution advised: combo may incr. budesonide levels, risk of systemic corticosteroid effects incl. Cushing syndrome and adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited, additive effects)

  • budesonide nasal
  • Lifyorli (relacorilant)
    +
    budesonide nasal
    1 interaction

    Caution Advised

    relacorilant + budesonide nasal

    caution advised: combo may incr. budesonide levels, risk of systemic corticosteroid effects incl. Cushing syndrome and adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited, additive effects)

  • busulfan
  • Lifyorli (relacorilant)
    +
    busulfan
    1 interaction

    Caution Advised

    relacorilant + busulfan

    caution advised: combo may incr. risk of serious infection (additive effects)

  • canakinumab
  • Lifyorli (relacorilant)
    +
    canakinumab
    1 interaction

    Caution Advised

    relacorilant + canakinumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • cannabis
  • Lifyorli (relacorilant)
    +
    cannabis
    1 interaction

    Caution Advised

    relacorilant + cannabis

    caution advised: combo may incr. cannabis levels, risk of adverse effects (hepatic metabolism inhibited)

  • capmatinib
  • Lifyorli (relacorilant)
    +
    capmatinib
    1 interaction

    Caution Advised

    relacorilant + capmatinib

    caution advised: combo may incr. capmatinib levels, risk of adverse effects (hepatic metabolism inhibited)

  • carboplatin
  • Lifyorli (relacorilant)
    +
    carboplatin
    1 interaction

    Caution Advised

    relacorilant + carboplatin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • carfilzomib
  • Lifyorli (relacorilant)
    +
    carfilzomib
    1 interaction

    Caution Advised

    relacorilant + carfilzomib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • carmustine
  • Lifyorli (relacorilant)
    +
    carmustine
    1 interaction

    Caution Advised

    relacorilant + carmustine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • cenobamate
  • Lifyorli (relacorilant)
    +
    cenobamate
    1 interaction

    Caution Advised

    relacorilant + cenobamate

    caution advised: combo may decr. relacorilant levels, efficacy (hepatic metabolism possibly induced)

  • certolizumab pegol
  • Lifyorli (relacorilant)
    +
    certolizumab pegol
    1 interaction

    Caution Advised

    relacorilant + certolizumab pegol

    caution advised: combo may incr. risk of serious infection (additive effects)

  • chlorambucil
  • Lifyorli (relacorilant)
    +
    chlorambucil
    1 interaction

    Caution Advised

    relacorilant + chlorambucil

    caution advised: combo may incr. risk of serious infection (additive effects)

  • chlordiazepoxide
  • Lifyorli (relacorilant)
    +
    chlordiazepoxide
    1 interaction

    Caution Advised

    relacorilant + chlordiazepoxide

    caution advised: combo may incr. chlordiazepoxide levels, risk of adverse effects (hepatic metabolism inhibited)

  • ciltacabtagene autoleucel
  • Lifyorli (relacorilant)
    +
    ciltacabtagene autoleucel
    1 interaction

    Caution Advised

    relacorilant + ciltacabtagene autoleucel

    caution advised: combo may incr. risk of serious infection (additive effects)

  • cisplatin
  • Lifyorli (relacorilant)
    +
    cisplatin
    1 interaction

    Caution Advised

    relacorilant + cisplatin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • cladribine injection
  • Lifyorli (relacorilant)
    +
    cladribine injection
    1 interaction

    Caution Advised

    relacorilant + cladribine injection

    caution advised: combo may incr. risk of serious infection (additive effects)

  • clindamycin
  • Lifyorli (relacorilant)
    +
    clindamycin
    1 interaction

    Caution Advised

    relacorilant + clindamycin

    caution advised: combo may incr. clindamycin levels, risk of adverse effects (hepatic metabolism inhibited)

  • clobetasol ophthalmic
  • Lifyorli (relacorilant)
    +
    clobetasol ophthalmic
    1 interaction

    Caution Advised

    relacorilant + clobetasol ophthalmic

    caution advised: combo may incr. risk of serious infection (additive effects)

  • clofarabine
  • Lifyorli (relacorilant)
    +
    clofarabine
    1 interaction

    Caution Advised

    relacorilant + clofarabine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • cobicistat
  • Lifyorli (relacorilant)
    +
    cobicistat
    1 interaction

    Caution Advised

    relacorilant + cobicistat

    caution advised: combo may incr. cobicistat levels, risk of adverse effects (hepatic metabolism inhibited)

  • coccidioides immitis skin test antigen
  • Lifyorli (relacorilant)
    +
    coccidioides immitis skin test antigen
    1 interaction

    Caution Advised

    relacorilant + coccidioides immitis skin test antigen

    caution advised: combo may incr. risk of serious infection (additive effects)

  • corticotropin
  • Lifyorli (relacorilant)
    +
    corticotropin
    1 interaction

    Caution Advised

    relacorilant + corticotropin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • crovalimab
  • Lifyorli (relacorilant)
    +
    crovalimab
    1 interaction

    Caution Advised

    relacorilant + crovalimab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • cytarabine
  • Lifyorli (relacorilant)
    +
    cytarabine
    1 interaction

    Caution Advised

    relacorilant + cytarabine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • dacarbazine
  • Lifyorli (relacorilant)
    +
    dacarbazine
    1 interaction

    Caution Advised

    relacorilant + dacarbazine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • dactinomycin
  • Lifyorli (relacorilant)
    +
    dactinomycin
    1 interaction

    Caution Advised

    relacorilant + dactinomycin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • danicopan
  • Lifyorli (relacorilant)
    +
    danicopan
    1 interaction

    Caution Advised

    relacorilant + danicopan

    caution advised: combo may incr. risk of serious infection (additive effects)

  • daratumumab
  • Lifyorli (relacorilant)
    +
    daratumumab
    1 interaction

    Caution Advised

    relacorilant + daratumumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • darolutamide
  • Lifyorli (relacorilant)
    +
    darolutamide
    1 interaction

    Caution Advised

    relacorilant + darolutamide

    if also combined w/ P-gp inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effect (hepatic metabolism inhibited)

  • darunavir
  • Lifyorli (relacorilant)
    +
    darunavir
    1 interaction

    Caution Advised

    relacorilant + darunavir

    caution advised: combo may incr. darunavir levels, risk of adverse effects (hepatic metabolism inhibited)

  • daunorubicin
  • Lifyorli (relacorilant)
    +
    daunorubicin
    1 interaction

    Caution Advised

    relacorilant + daunorubicin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • delgocitinib topical
  • Lifyorli (relacorilant)
    +
    delgocitinib topical
    1 interaction

    Caution Advised

    relacorilant + delgocitinib topical

    caution advised: combo may incr. risk of serious infection (additive effects)

  • deucravacitinib
  • Lifyorli (relacorilant)
    +
    deucravacitinib
    1 interaction

    Caution Advised

    relacorilant + deucravacitinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • dexamethasone ophthalmic
  • Lifyorli (relacorilant)
    +
    dexamethasone ophthalmic
    1 interaction

    Caution Advised

    relacorilant + dexamethasone ophthalmic

    caution advised: combo may incr. risk of serious infection (additive effects)

  • difluprednate ophthalmic
  • Lifyorli (relacorilant)
    +
    difluprednate ophthalmic
    1 interaction

    Caution Advised

    relacorilant + difluprednate ophthalmic

    caution advised: combo may incr. risk of serious infection (additive effects)

  • dimethyl fumarate
  • Lifyorli (relacorilant)
    +
    dimethyl fumarate
    1 interaction

    Caution Advised

    relacorilant + dimethyl fumarate

    caution advised: combo may incr. risk of serious infection (additive effects)

  • dinutuximab
  • Lifyorli (relacorilant)
    +
    dinutuximab
    1 interaction

    Caution Advised

    relacorilant + dinutuximab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • diroximel fumarate
  • Lifyorli (relacorilant)
    +
    diroximel fumarate
    1 interaction

    Caution Advised

    relacorilant + diroximel fumarate

    caution advised: combo may incr. risk of serious infection (additive effects)

  • doravirine
  • Lifyorli (relacorilant)
    +
    doravirine
    1 interaction

    Caution Advised

    relacorilant + doravirine

    caution advised: combo may incr. doravirine levels, risk of adverse effects (hepatic metabolism inhibited)

  • doxazosin
  • Lifyorli (relacorilant)
    +
    doxazosin
    1 interaction

    Caution Advised

    relacorilant + doxazosin

    caution advised: combo may incr. doxazosin levels, risk of adverse effects (hepatic metabolism inhibited)

  • dronabinol
  • Lifyorli (relacorilant)
    +
    dronabinol
    1 interaction

    Caution Advised

    relacorilant + dronabinol

    caution advised: combo may incr. dronabinol levels, risk of adverse effects (hepatic metabolism inhibited)

  • dupilumab
  • Lifyorli (relacorilant)
    +
    dupilumab
    1 interaction

    Caution Advised

    relacorilant + dupilumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • dutasteride
  • Lifyorli (relacorilant)
    +
    dutasteride
    1 interaction

    Caution Advised

    relacorilant + dutasteride

    caution advised: combo may incr. dutasteride levels, risk of adverse effects (hepatic metabolism inhibited)

  • eculizumab
  • Lifyorli (relacorilant)
    +
    eculizumab
    1 interaction

    Caution Advised

    relacorilant + eculizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • efgartigimod alfa
  • Lifyorli (relacorilant)
    +
    efgartigimod alfa
    1 interaction

    Caution Advised

    relacorilant + efgartigimod alfa

    caution advised: combo may incr. risk of serious infection (additive effects)

  • elotuzumab
  • Lifyorli (relacorilant)
    +
    elotuzumab
    1 interaction

    Caution Advised

    relacorilant + elotuzumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • elranatamab
  • Lifyorli (relacorilant)
    +
    elranatamab
    1 interaction

    Caution Advised

    relacorilant + elranatamab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • elvitegravir
  • Lifyorli (relacorilant)
    +
    elvitegravir
    1 interaction

    Caution Advised

    relacorilant + elvitegravir

    caution advised: combo may incr. elvitegravir levels, risk of adverse effects (hepatic metabolism inhibited)

  • emapalumab
  • Lifyorli (relacorilant)
    +
    emapalumab
    1 interaction

    Caution Advised

    relacorilant + emapalumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • epcoritamab
  • Lifyorli (relacorilant)
    +
    epcoritamab
    1 interaction

    Caution Advised

    relacorilant + epcoritamab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • epirubicin
  • Lifyorli (relacorilant)
    +
    epirubicin
    1 interaction

    Caution Advised

    relacorilant + epirubicin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • eravacycline
  • Lifyorli (relacorilant)
    +
    eravacycline
    1 interaction

    Caution Advised

    relacorilant + eravacycline

    caution advised: combo may incr. eravacycline levels, risk of adverse effects (hepatic metabolism inhibited)

  • eribulin
  • Lifyorli (relacorilant)
    +
    eribulin
    1 interaction

    Caution Advised

    relacorilant + eribulin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • estradiol (hormone replacement)
  • Lifyorli (relacorilant)
    +
    estradiol (hormone replacement)
    1 interaction

    Caution Advised

    relacorilant + estradiol (hormone replacement)

    caution advised: combo may incr. estradiol levels, risk of adverse effects (hepatic metabolism inhibited)

  • estrogens, esterified (hormone replacement)
  • Lifyorli (relacorilant)
    +
    estrogens, esterified (hormone replacement)
    1 interaction

    Caution Advised

    relacorilant + estrogens, esterified (hormone replacement)

    caution advised: combo may incr. estrogen levels, risk of adverse effects (hepatic metabolism inhibited)

  • etanercept
  • Lifyorli (relacorilant)
    +
    etanercept
    1 interaction

    Caution Advised

    relacorilant + etanercept

    caution advised: combo may incr. risk of serious infection (additive effects)

  • ethinyl estradiol (hormone replacement)
  • Lifyorli (relacorilant)
    +
    ethinyl estradiol (hormone replacement)
    1 interaction

    Caution Advised

    relacorilant + ethinyl estradiol (hormone replacement)

    caution advised: combo may incr. ethinyl estradiol levels, risk of adverse effects (hepatic metabolism inhibited)

  • etravirine
  • Lifyorli (relacorilant)
    +
    etravirine
    1 interaction

    Caution Advised

    relacorilant + etravirine

    caution advised: combo may incr. etravirine levels, risk of adverse effects; may decr. relacorilant levels, efficacy (hepatic metabolism inhibited; hepatic metabolism possibly induced)

  • fingolimod
  • Lifyorli (relacorilant)
    +
    fingolimod
    1 interaction

    Caution Advised

    relacorilant + fingolimod

    caution advised during and x2mo after fingolimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

  • floxuridine
  • Lifyorli (relacorilant)
    +
    floxuridine
    1 interaction

    Caution Advised

    relacorilant + floxuridine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • fludarabine
  • Lifyorli (relacorilant)
    +
    fludarabine
    1 interaction

    Caution Advised

    relacorilant + fludarabine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • flunisolide nasal
  • Lifyorli (relacorilant)
    +
    flunisolide nasal
    1 interaction

    Caution Advised

    relacorilant + flunisolide nasal

    caution advised: combo may incr. risk of serious infection (additive effects)

  • fluocinolone intravitreal
  • Lifyorli (relacorilant)
    +
    fluocinolone intravitreal
    1 interaction

    Caution Advised

    relacorilant + fluocinolone intravitreal

    caution advised: combo may incr. risk of serious infection (additive effects)

  • fluorometholone ophthalmic
  • Lifyorli (relacorilant)
    +
    fluorometholone ophthalmic
    1 interaction

    Caution Advised

    relacorilant + fluorometholone ophthalmic

    caution advised: combo may incr. risk of serious infection (additive effects)

  • fluticasone furoate
  • Lifyorli (relacorilant)
    +
    fluticasone furoate
    1 interaction

    Caution Advised

    relacorilant + fluticasone furoate

    caution advised: combo may incr. plasma fluticasone exposure, risk of systemic corticosteroid effects incl. Cushing syndrome and adrenal suppression, serious infection (hepatic metabolism inhibited, additive effects)

  • fruquintinib
  • Lifyorli (relacorilant)
    +
    fruquintinib
    1 interaction

    Caution Advised

    relacorilant + fruquintinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • gefitinib
  • Lifyorli (relacorilant)
    +
    gefitinib
    1 interaction

    Caution Advised

    relacorilant + gefitinib

    caution advised: combo may incr. gefitinib levels, risk of adverse effects (hepatic metabolism inhibited)

  • gemtuzumab ozogamicin
  • Lifyorli (relacorilant)
    +
    gemtuzumab ozogamicin
    1 interaction

    Caution Advised

    relacorilant + gemtuzumab ozogamicin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • glofitamab
  • Lifyorli (relacorilant)
    +
    glofitamab
    1 interaction

    Caution Advised

    relacorilant + glofitamab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • golimumab
  • Lifyorli (relacorilant)
    +
    golimumab
    1 interaction

    Caution Advised

    relacorilant + golimumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • guselkumab
  • Lifyorli (relacorilant)
    +
    guselkumab
    1 interaction

    Caution Advised

    relacorilant + guselkumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • hydrocortisone ophthalmic
  • Lifyorli (relacorilant)
    +
    hydrocortisone ophthalmic
    1 interaction

    Caution Advised

    relacorilant + hydrocortisone ophthalmic

    caution advised: combo may incr. risk of serious infection (additive effects)

  • ibritumomab tiuxetan
  • Lifyorli (relacorilant)
    +
    ibritumomab tiuxetan
    1 interaction

    Caution Advised

    relacorilant + ibritumomab tiuxetan

    caution advised: combo may incr. risk of serious infection (additive effects)

  • icotrokinra
  • Lifyorli (relacorilant)
    +
    icotrokinra
    1 interaction

    Caution Advised

    relacorilant + icotrokinra

    caution advised: combo may incr. risk of serious infection (additive effects)

  • idarubicin
  • Lifyorli (relacorilant)
    +
    idarubicin
    1 interaction

    Caution Advised

    relacorilant + idarubicin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • idecabtagene vicleucel
  • Lifyorli (relacorilant)
    +
    idecabtagene vicleucel
    1 interaction

    Caution Advised

    relacorilant + idecabtagene vicleucel

    caution advised: combo may incr. risk of serious infection (additive effects)

  • ifosfamide
  • Lifyorli (relacorilant)
    +
    ifosfamide
    1 interaction

    Caution Advised

    relacorilant + ifosfamide

    caution advised: combo may decr. ifosfamide active metabolite levels, efficacy; may incr. risk of serious infection (hepatic metabolism inhibited, decr. active metabolite formation; additive effects)

  • inebilizumab
  • Lifyorli (relacorilant)
    +
    inebilizumab
    1 interaction

    Caution Advised

    relacorilant + inebilizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • infliximab
  • Lifyorli (relacorilant)
    +
    infliximab
    1 interaction

    Caution Advised

    relacorilant + infliximab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • inotuzumab ozogamicin
  • Lifyorli (relacorilant)
    +
    inotuzumab ozogamicin
    1 interaction

    Caution Advised

    relacorilant + inotuzumab ozogamicin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • iptacopan
  • Lifyorli (relacorilant)
    +
    iptacopan
    1 interaction

    Caution Advised

    relacorilant + iptacopan

    caution advised: combo may incr. risk of serious infection (additive effects)

  • isatuximab
  • Lifyorli (relacorilant)
    +
    isatuximab
    1 interaction

    Caution Advised

    relacorilant + isatuximab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • isradipine
  • Lifyorli (relacorilant)
    +
    isradipine
    1 interaction

    Caution Advised

    relacorilant + isradipine

    caution advised: combo may incr. isradipine levels, risk of hypotension, other adverse effects (hepatic metabolism inhibited)

  • ixekizumab
  • Lifyorli (relacorilant)
    +
    ixekizumab
    1 interaction

    Caution Advised

    relacorilant + ixekizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • lebrikizumab
  • Lifyorli (relacorilant)
    +
    lebrikizumab
    1 interaction

    Caution Advised

    relacorilant + lebrikizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • lenalidomide
  • Lifyorli (relacorilant)
    +
    lenalidomide
    1 interaction

    Caution Advised

    relacorilant + lenalidomide

    caution advised: combo may incr. risk of serious infection (additive effects)

  • lifileucel
  • Lifyorli (relacorilant)
    +
    lifileucel
    1 interaction

    Caution Advised

    relacorilant + lifileucel

    caution advised: combo may incr. risk of serious infection (additive effects)

  • linvoseltamab
  • Lifyorli (relacorilant)
    +
    linvoseltamab
    1 interaction

    Caution Advised

    relacorilant + linvoseltamab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • lisocabtagene maraleucel
  • Lifyorli (relacorilant)
    +
    lisocabtagene maraleucel
    1 interaction

    Caution Advised

    relacorilant + lisocabtagene maraleucel

    caution advised: combo may incr. risk of serious infection (additive effects)

  • lomustine
  • Lifyorli (relacorilant)
    +
    lomustine
    1 interaction

    Caution Advised

    relacorilant + lomustine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • loncastuximab tesirine
  • Lifyorli (relacorilant)
    +
    loncastuximab tesirine
    1 interaction

    Caution Advised

    relacorilant + loncastuximab tesirine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • lopinavir/ritonavir
  • Lifyorli (relacorilant)
    +
    lopinavir/ ritonavir
    1 interaction

    Caution Advised

    relacorilant + lopinavir/ ritonavir

    caution advised: combo may decr. relacorilant levels, efficacy (hepatic metabolism possibly induced)

  • loteprednol ophthalmic
  • Lifyorli (relacorilant)
    +
    loteprednol ophthalmic
    1 interaction

    Caution Advised

    relacorilant + loteprednol ophthalmic

    caution advised: combo may incr. risk of serious infection (additive effects)

  • melphalan
  • Lifyorli (relacorilant)
    +
    melphalan
    1 interaction

    Caution Advised

    relacorilant + melphalan

    caution advised: combo may incr. risk of serious infection (additive effects)

  • mirikizumab
  • Lifyorli (relacorilant)
    +
    mirikizumab
    1 interaction

    Caution Advised

    relacorilant + mirikizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • mirvetuximab soravtansine
  • Lifyorli (relacorilant)
    +
    mirvetuximab soravtansine
    1 interaction

    Caution Advised

    relacorilant + mirvetuximab soravtansine

    caution advised: combo may incr. microtubule inhibitor (DM4) levels, risk of adverse effects (hepatic metabolism inhibited)

  • mitomycin
  • Lifyorli (relacorilant)
    +
    mitomycin
    1 interaction

    Caution Advised

    relacorilant + mitomycin

    caution advised; risk may be lower w/ intravesical mitomycin administration: combo may incr. risk of serious infection (additive effects)

  • mitoxantrone
  • Lifyorli (relacorilant)
    +
    mitoxantrone
    1 interaction

    Caution Advised

    relacorilant + mitoxantrone

    caution advised: combo may incr. risk of serious infection (additive effects)

  • modafinil
  • Lifyorli (relacorilant)
    +
    modafinil
    1 interaction

    Caution Advised

    relacorilant + modafinil

    caution advised: combo may incr. modafinil levels, adverse effects; may decr. relacorilant levels, efficacy (hepatic metabolism inhibited; hepatic metabolism possibly induced)

  • mogamulizumab
  • Lifyorli (relacorilant)
    +
    mogamulizumab
    1 interaction

    Caution Advised

    relacorilant + mogamulizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • momelotinib
  • Lifyorli (relacorilant)
    +
    momelotinib
    1 interaction

    Caution Advised

    relacorilant + momelotinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • mometasone implant
  • Lifyorli (relacorilant)
    +
    mometasone implant
    1 interaction

    Caution Advised

    relacorilant + mometasone implant

    caution advised: combo may incr. mometasone levels, risk of serious infection, systemic corticosteroid effects incl. Cushing syndrome, adrenal suppression, other adverse effects (hepatic metabolism inhibited, additive effects)

  • mometasone inhaled
  • Lifyorli (relacorilant)
    +
    mometasone inhaled
    1 interaction

    Caution Advised

    relacorilant + mometasone inhaled

    caution advised: combo may incr. mometasone levels, risk of systemic corticosteroid effects incl. Cushing syndrome, adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited, additive effects)

  • mometasone nasal
  • Lifyorli (relacorilant)
    +
    mometasone nasal
    1 interaction

    Caution Advised

    relacorilant + mometasone nasal

    caution advised: combo may incr. mometasone levels, risk of systemic corticosteroid effects incl. Cushing syndrome, adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited, additive effects)

  • monomethyl fumarate
  • Lifyorli (relacorilant)
    +
    monomethyl fumarate
    1 interaction

    Caution Advised

    relacorilant + monomethyl fumarate

    caution advised: combo may incr. risk of serious infection (additive effects)

  • mosunetuzumab
  • Lifyorli (relacorilant)
    +
    mosunetuzumab
    1 interaction

    Caution Advised

    relacorilant + mosunetuzumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • nadofaragene firadenovec intravesical
  • Lifyorli (relacorilant)
    +
    nadofaragene firadenovec intravesical
    1 interaction

    Caution Advised

    relacorilant + nadofaragene firadenovec intravesical

    caution advised: combo may incr. risk of disseminated adenovirus infection (immunosuppressive effects)

  • nafcillin
  • Lifyorli (relacorilant)
    +
    nafcillin
    1 interaction

    Caution Advised

    relacorilant + nafcillin

    caution advised: combo may decr. relacorilant levels, efficacy (hepatic metabolism possibly induced)

  • naldemedine
  • Lifyorli (relacorilant)
    +
    naldemedine
    1 interaction

    Caution Advised

    relacorilant + naldemedine

    caution advised: combo may incr. naldemedine levels, risk of adverse effects (hepatic metabolism inhibited)

  • narsoplimab
  • Lifyorli (relacorilant)
    +
    narsoplimab
    1 interaction

    Caution Advised

    relacorilant + narsoplimab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • nelarabine
  • Lifyorli (relacorilant)
    +
    nelarabine
    1 interaction

    Caution Advised

    relacorilant + nelarabine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • nipocalimab
  • Lifyorli (relacorilant)
    +
    nipocalimab
    1 interaction

    Caution Advised

    relacorilant + nipocalimab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • obecabtagene autoleucel
  • Lifyorli (relacorilant)
    +
    obecabtagene autoleucel
    1 interaction

    Caution Advised

    relacorilant + obecabtagene autoleucel

    caution advised: combo may incr. risk of serious infection (additive effects)

  • obinutuzumab
  • Lifyorli (relacorilant)
    +
    obinutuzumab
    1 interaction

    Caution Advised

    relacorilant + obinutuzumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • ocrelizumab
  • Lifyorli (relacorilant)
    +
    ocrelizumab
    1 interaction

    Caution Advised

    relacorilant + ocrelizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • ofatumumab
  • Lifyorli (relacorilant)
    +
    ofatumumab
    1 interaction

    Caution Advised

    relacorilant + ofatumumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • ospemifene
  • Lifyorli (relacorilant)
    +
    ospemifene
    1 interaction

    Caution Advised

    relacorilant + ospemifene

    caution advised: combo may incr. ospemifene levels, risk of adverse effects (hepatic metabolism inhibited)

  • oxaliplatin
  • Lifyorli (relacorilant)
    +
    oxaliplatin
    1 interaction

    Caution Advised

    relacorilant + oxaliplatin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • oxybutynin
  • Lifyorli (relacorilant)
    +
    oxybutynin
    1 interaction

    Caution Advised

    relacorilant + oxybutynin

    caution advised: combo may incr. oxybutynin levels, risk of adverse effects (hepatic metabolism inhibited)

  • ozanimod
  • Lifyorli (relacorilant)
    +
    ozanimod
    1 interaction

    Caution Advised

    relacorilant + ozanimod

    caution advised during and x3mo after ozanimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

  • pegcetacoplan
  • Lifyorli (relacorilant)
    +
    pegcetacoplan
    1 interaction

    Caution Advised

    relacorilant + pegcetacoplan

    caution advised: combo may incr. risk of serious infection (additive effects)

  • pentostatin
  • Lifyorli (relacorilant)
    +
    pentostatin
    1 interaction

    Caution Advised

    relacorilant + pentostatin

    caution advised: combo may incr. risk of serious infection (additive effects)

  • ponesimod
  • Lifyorli (relacorilant)
    +
    ponesimod
    1 interaction

    Caution Advised

    relacorilant + ponesimod

    caution advised during and x1-2wk after ponesimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

  • pozelimab
  • Lifyorli (relacorilant)
    +
    pozelimab
    1 interaction

    Caution Advised

    relacorilant + pozelimab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • prednisolone ophthalmic
  • Lifyorli (relacorilant)
    +
    prednisolone ophthalmic
    1 interaction

    Caution Advised

    relacorilant + prednisolone ophthalmic

    caution advised: combo may incr. risk of serious infection (additive effects)

  • procarbazine
  • Lifyorli (relacorilant)
    +
    procarbazine
    1 interaction

    Caution Advised

    relacorilant + procarbazine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • ramelteon
  • Lifyorli (relacorilant)
    +
    ramelteon
    1 interaction

    Caution Advised

    relacorilant + ramelteon

    caution advised: combo may incr. ramelteon levels, risk of adverse effects (hepatic metabolism inhibited)

  • ravulizumab
  • Lifyorli (relacorilant)
    +
    ravulizumab
    1 interaction

    Caution Advised

    relacorilant + ravulizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • rifapentine
  • Lifyorli (relacorilant)
    +
    rifapentine
    1 interaction

    Caution Advised

    relacorilant + rifapentine

    caution advised: combo may decr. relacorilant levels, efficacy (hepatic metabolism possibly induced)

  • rilonacept
  • Lifyorli (relacorilant)
    +
    rilonacept
    1 interaction

    Caution Advised

    relacorilant + rilonacept

    caution advised: combo may incr. risk of serious infection (additive effects)

  • ripretinib
  • Lifyorli (relacorilant)
    +
    ripretinib
    1 interaction

    Caution Advised

    relacorilant + ripretinib

    caution advised: combo may incr. ripretinib and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

  • risankizumab
  • Lifyorli (relacorilant)
    +
    risankizumab
    1 interaction

    Caution Advised

    relacorilant + risankizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • risperidone
  • Lifyorli (relacorilant)
    +
    risperidone
    1 interaction

    Caution Advised

    relacorilant + risperidone

    caution advised: combo may incr. risperidone levels, risk of adverse effects (hepatic metabolism inhibited)

  • ritlecitinib
  • Lifyorli (relacorilant)
    +
    ritlecitinib
    1 interaction

    Caution Advised

    relacorilant + ritlecitinib

    caution advised: combo may incr. risk of serious infection (additive effects)

  • roflumilast
  • Lifyorli (relacorilant)
    +
    roflumilast
    1 interaction

    Caution Advised

    relacorilant + roflumilast

    caution advised: combo may incr. roflumilast levels, risk of adverse effects (hepatic metabolism inhibited)

  • roflumilast topical
  • Lifyorli (relacorilant)
    +
    roflumilast topical
    1 interaction

    Caution Advised

    relacorilant + roflumilast topical

    caution advised: combo may incr. roflumilast levels, risk of adverse effects (hepatic metabolism inhibited)

  • rozanolixizumab
  • Lifyorli (relacorilant)
    +
    rozanolixizumab
    1 interaction

    Caution Advised

    relacorilant + rozanolixizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • secukinumab
  • Lifyorli (relacorilant)
    +
    secukinumab
    1 interaction

    Caution Advised

    relacorilant + secukinumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • seladelpar
  • Lifyorli (relacorilant)
    +
    seladelpar
    1 interaction

    Caution Advised

    relacorilant + seladelpar

    caution advised if CYP2C9 poor metabolizer or if also combined with moderate CYP2C9 inhibitor: combo may incr. seladelpar levels, risk of adverse effects (hepatic metabolism inhibited)

  • selinexor
  • Lifyorli (relacorilant)
    +
    selinexor
    1 interaction

    Caution Advised

    relacorilant + selinexor

    caution advised: combo may incr. risk of serious infection (additive effects)

  • sibeprenlimab
  • Lifyorli (relacorilant)
    +
    sibeprenlimab
    1 interaction

    Caution Advised

    relacorilant + sibeprenlimab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • siltuximab
  • Lifyorli (relacorilant)
    +
    siltuximab
    1 interaction

    Caution Advised

    relacorilant + siltuximab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • sirolimus topical
  • Lifyorli (relacorilant)
    +
    sirolimus topical
    1 interaction

    Caution Advised

    relacorilant + sirolimus topical

    caution advised: combo may incr. sirolimus levels, risk of adverse effects (hepatic metabolism inhibited)

  • sotorasib
  • Lifyorli (relacorilant)
    +
    sotorasib
    1 interaction

    Caution Advised

    relacorilant + sotorasib

    caution advised: combo may decr. relacorilant levels, efficacy (hepatic metabolism possibly induced)

  • spesolimab
  • Lifyorli (relacorilant)
    +
    spesolimab
    1 interaction

    Caution Advised

    relacorilant + spesolimab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • sutimlimab
  • Lifyorli (relacorilant)
    +
    sutimlimab
    1 interaction

    Caution Advised

    relacorilant + sutimlimab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • tacrolimus topical
  • Lifyorli (relacorilant)
    +
    tacrolimus topical
    1 interaction

    Caution Advised

    relacorilant + tacrolimus topical

    caution advised: combo may incr. tacrolimus levels, risk of adverse effects (hepatic metabolism inhibited)

  • tafasitamab
  • Lifyorli (relacorilant)
    +
    tafasitamab
    1 interaction

    Caution Advised

    relacorilant + tafasitamab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • talquetamab
  • Lifyorli (relacorilant)
    +
    talquetamab
    1 interaction

    Caution Advised

    relacorilant + talquetamab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • tamoxifen
  • Lifyorli (relacorilant)
    +
    tamoxifen
    1 interaction

    Caution Advised

    relacorilant + tamoxifen

    caution advised: combo may incr. tamoxifen levels, risk of adverse effects, decr. active tamoxifen metabolite levels, efficacy (hepatic metabolism inhibited, decr. conversion to active metabolite)

  • tarlatamab
  • Lifyorli (relacorilant)
    +
    tarlatamab
    1 interaction

    Caution Advised

    relacorilant + tarlatamab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • teclistamab
  • Lifyorli (relacorilant)
    +
    teclistamab
    1 interaction

    Caution Advised

    relacorilant + teclistamab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • telisotuzumab vedotin
  • Lifyorli (relacorilant)
    +
    telisotuzumab vedotin
    1 interaction

    Caution Advised

    relacorilant + telisotuzumab vedotin

    caution advised: combo may incr. telisotuzumab vedotin levels, incr. risk of peripheral neuropathy, other adverse effects (hepatic metabolism inhibited)

  • temozolomide
  • Lifyorli (relacorilant)
    +
    temozolomide
    1 interaction

    Caution Advised

    relacorilant + temozolomide

    caution advised: combo may incr. risk of serious infection (additive effects)

  • tezepelumab
  • Lifyorli (relacorilant)
    +
    tezepelumab
    1 interaction

    Caution Advised

    relacorilant + tezepelumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • thioguanine
  • Lifyorli (relacorilant)
    +
    thioguanine
    1 interaction

    Caution Advised

    relacorilant + thioguanine

    caution advised: combo may incr. risk of serious infection (additive effects)

  • tildrakizumab
  • Lifyorli (relacorilant)
    +
    tildrakizumab
    1 interaction

    Caution Advised

    relacorilant + tildrakizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • tinidazole
  • Lifyorli (relacorilant)
    +
    tinidazole
    1 interaction

    Caution Advised

    relacorilant + tinidazole

    caution advised: combo may incr. tinidazole levels, risk of adverse effects (hepatic metabolism inhibited)

  • tisagenlecleucel
  • Lifyorli (relacorilant)
    +
    tisagenlecleucel
    1 interaction

    Caution Advised

    relacorilant + tisagenlecleucel

    caution advised: combo may incr. risk of serious infection (additive effects)

  • tisotumab vedotin
  • Lifyorli (relacorilant)
    +
    tisotumab vedotin
    1 interaction

    Caution Advised

    relacorilant + tisotumab vedotin

    caution advised: combo may incr. tisotumab vedotin levels, risk of ocular toxicity, peripheral neuropathy, other adverse effects (hepatic metabolism inhibited)

  • topiramate
  • Lifyorli (relacorilant)
    +
    topiramate
    1 interaction

    Caution Advised

    relacorilant + topiramate

    caution advised: combo may incr. topiramate levels, risk of adverse effects (hepatic metabolism inhibited)

  • topotecan
  • Lifyorli (relacorilant)
    +
    topotecan
    1 interaction

    Caution Advised

    relacorilant + topotecan

    caution advised: combo may incr. risk of serious infection (additive effects)

  • tradipitant
  • Lifyorli (relacorilant)
    +
    tradipitant
    1 interaction

    Caution Advised

    relacorilant + tradipitant

    caution advised: combo may incr. tradipitant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • tralokinumab
  • Lifyorli (relacorilant)
    +
    tralokinumab
    1 interaction

    Caution Advised

    relacorilant + tralokinumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • tuberculin purified protein derivative
  • Lifyorli (relacorilant)
    +
    tuberculin purified protein derivative
    1 interaction

    Caution Advised

    relacorilant + tuberculin purified protein derivative

    caution advised during and x5-6wk after relacorilant tx: combo may interfere with test results (additive effects)

  • tucatinib
  • Lifyorli (relacorilant)
    +
    tucatinib
    1 interaction

    Caution Advised

    relacorilant + tucatinib

    caution advised: combo may decr. tucatinib levels, efficacy (hepatic metabolism induced)

  • ublituximab
  • Lifyorli (relacorilant)
    +
    ublituximab
    1 interaction

    Caution Advised

    relacorilant + ublituximab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • ustekinumab
  • Lifyorli (relacorilant)
    +
    ustekinumab
    1 interaction

    Caution Advised

    relacorilant + ustekinumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • vedolizumab
  • Lifyorli (relacorilant)
    +
    vedolizumab
    1 interaction

    Caution Advised

    relacorilant + vedolizumab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • velpatasvir
  • Lifyorli (relacorilant)
    +
    velpatasvir
    1 interaction

    Caution Advised

    relacorilant + velpatasvir

    caution advised: combo may decr. velpatasvir levels, efficacy (hepatic metabolism induced)

  • venlafaxine
  • Lifyorli (relacorilant)
    +
    venlafaxine
    1 interaction

    Caution Advised

    relacorilant + venlafaxine

    caution advised: combo may incr. venlafaxine levels, risk of adverse effects (hepatic metabolism inhibited)

  • vilobelimab
  • Lifyorli (relacorilant)
    +
    vilobelimab
    1 interaction

    Caution Advised

    relacorilant + vilobelimab

    caution advised: combo may incr. risk of serious infection (additive effects)

  • voxilaprevir
  • Lifyorli (relacorilant)
    +
    voxilaprevir
    1 interaction

    Caution Advised

    relacorilant + voxilaprevir

    caution advised: combo may decr. voxilaprevir levels, efficacy (hepatic metabolism induced)

  • zaleplon
  • Lifyorli (relacorilant)
    +
    zaleplon
    1 interaction

    Caution Advised

    relacorilant + zaleplon

    caution advised: combo may incr. zaleplon levels, risk of adverse effects (hepatic metabolism inhibited)

  • zileuton
  • Lifyorli (relacorilant)
    +
    zileuton
    1 interaction

    Caution Advised

    relacorilant + zileuton

    caution advised: combo may incr. zileuton levels, risk of adverse effects (hepatic metabolism inhibited)

  • zilucoplan
  • Lifyorli (relacorilant)
    +
    zilucoplan
    1 interaction

    Caution Advised

    relacorilant + zilucoplan

    caution advised: combo may incr. risk of serious infection (additive effects)

Adverse Reactions .

Serious Reactions

    com.epocrates.rxweb.beans.StringCollection@2307167e
  • neutropenia
  • febrile neutropenia
  • infection, severe
  • adrenal insufficiency
  • glucocorticoid-treated condition exacerbation
  • pleural effusion

Common Reactions

    com.epocrates.rxweb.beans.StringCollection@42f00e17
  • Hgb decr.
  • neutrophils decr.
  • fatigue
  • nausea
  • diarrhea
  • Plt decr.
  • rash
  • appetite decr.
  • stomatitis
  • cough
  • edema
  • nail disorder
  • fever
  • dizziness
  • dysgeusia
  • dry eyes
  • hypotension
  • HTN
  • acute kidney injury
  • febrile neutropenia
  • syncope

Safety/Monitoring .

Monitoring Parameters
pregnancy test at baseline; CBC with diff before each paclitaxel albumin-bound dose and as clinically indicated; signs/symptoms of adrenal insufficiency

Pregnancy/Lactation .

Pregnancy

Clinical Summary

weigh risk/benefit during pregnancy; no human data available; risk of embryo-fetal death and structural abnormalities based on animal data at 0.6x systemic exposure

Individuals of Reproductive Potential

obtain pregnancy test before tx start; avoid pregnancy by using effective contraception during tx and x1wk after D/C in patients of childbearing potential and male patients

Lactation

Clinical Summary

avoid breastfeeding during tx and x1wk after D/C; no human data available to assess risk of infant harm or effects on milk production

Pharmacology .

com.epocrates.rxweb.beans.DrugOtherInfoBean@3a12b909

Metabolism: for relacorilant: liver primarily; CYP450: 3A substrate

Excretion: for relacorilant: feces 73% (<1% unchanged), urine 17% (<2% unchanged); Half-life: 27h

Subclass: Glucocorticoid Receptor Antagonists

Mechanism of Action
for relacorilant: inhibits cortisol-induced reduction of tumor necrosis factor alpha and interferon gamma, enhancing apoptosis and antitumor activity when administered with chemotherapy

Formulary .

No Formulary Selected

Manufacturer/Pricing .

Manufacturer: Corcept Therapeutics

com.epocrates.rxweb.beans.DrugOtherInfoBean@46354e8a

DEA/FDA: Rx

Retail Price

This information is currently not available for this drug.

Join Now to View Patient Handouts!

Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.

Current Members: Sign In.

Sign Up Now - It's Free >>

Pill Pictures

Join Now to View Pill Pictures!

Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.

Current Members: Sign In.

Sign Up Now - It's Free >>

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information